Page last updated: 2024-12-09

enclomiphene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Enclomiphene: The trans or (E)-isomer of clomiphene. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1548953
CHEMBL ID954
MeSH IDM0004591

Synonyms (83)

Synonym
BIDD:GT0216
BIDD:ER0223
2-[4-[(e)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine
BRD-K04218075-048-03-4
clomifeno
BPBIO1_000675
PRESTWICK3_000397
BSPBIO_000613
NCGC00179503-01
clomifene (tn)
clomifene (inn)
D07726
PRESTWICK2_000397
911-45-5
C06917
CLOMIPHENE ,
enclomiphene
clomifene
2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethylethanamine
trans-clomiphene
rmi 16,289
enclomifene
clomifen
ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethyl-, (e)-
trans-clomifene
trans-2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethylethanamine
transclomifenum
cisclomiphene
enclomifeno [inn-spanish]
ici 46476
enclomiphene [usan]
enclomifenum [inn-latin]
(e)-2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine
triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, (e)-
trans-2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine
MLS001304092
smr000718756
2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-n,n-diethylethanamine
HMS2090O17
isomer b
rmi-16289
isomer-b
rmi-16,289
CHEMBL954
clomiphene trans-form
ici-46476
15690-57-0
D08910
enclomiphene (usan)
AKOS005459442
NCGC00179503-02
enclomifeno
enclomifene [inn]
enclomifenum
r6d2ui4fls ,
unii-r6d2ui4fls
STK525981
2-{4-[(e)-2-chloro-1,2-diphenylethenyl]phenoxy}-n,n-diethylethanamine
HMS2232E06
chlomaphene
chloramifene
enclomiphene [who-dd]
clomiphene trans-form [mi]
{2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]ethyl}diethylamine
gtpl7619
2-[4-[(e)-2-chloro-1,2-di(phenyl)ethenyl]phenoxy]-n,n-diethylethanamine
smr004703502
MLS006011852
1-(p-.beta.-diethylaminoethoxyphenyl)-1,2-diphenyl-2-chloroethylene
cid_1548953
cid_6420009
bdbm55354
53q ,
HY-118861
2-[4-[(e)-2-chloro-1,2-diphenyl-vinyl]phenoxy]-n,n-diethyl-ethanamine
DB06735
1-[(e)-2-chloro-1,2-diphenylethenyl]-4-methoxybenzene; clomiphene
2-{4-[(e)-2-chloro-1,2-diphenylethenyl]phenoxy}-n,n-diethylethan-1-amine
ethanamine, 2-[4-[(1e)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethyl
ethanamine, 2-[4-[(1e)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethyl-
NCGC00179503-12
DTXSID201318048
CS-0069846

Research Excerpts

Treatment

Treatment with enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel in men with secondary hypogonadism.

ExcerptReferenceRelevance
"Enclomiphene citrate treatment maintained sperm concentrations in the normal range."( Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.
Kaminetsky, J; Kim, ED; McCullough, A, 2016
)
1.67
"Treatment with enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel in men with secondary hypogonadism. "( Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone.
Fontenot, GK; Hsu, K; Lipshultz, L; Nydell, J; Wiehle, RD; Wike, J, 2014
)
2.2

Toxicity

ExcerptReferenceRelevance
" Clomiphene citrate decreased the adverse effects of DES on appetite and body weight, and sharply decreased the gains in the pituitary and uterine weights from 243 to 80% and 59 to 14%, respectively."( Subacute toxicity of diethylstilboestrol and hexoestrol in the female rat, and the effects of clomiphene pretreatment.
Hart, JE, 1988
)
0.27
"Common safe physiological agents such as diuretics, hormones, and oral lipids can increase differences in NMR parameters between uninvolved breast tissue in tumor bearing animals and mammary carcinomas."( Improved NMR contrast for mouse mammary cancer by safe physiological agents.
Beall, PT, 1982
)
0.26
" Each agent is associated with its own specific adverse effects."( Adverse effects of fertility drugs.
Adashi, EY; Derman, SG, 1994
)
0.29
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" No adverse events were reported by any patients."( Clomiphene citrate is safe and effective for long-term management of hypogonadism.
Akhavan, A; Katz, DJ; Moskovic, DJ; Mulhall, JP; Park, K, 2012
)
0.38
" In contrast, CC+EB synergistically inflicted more adverse effects as apoptotic germ cells per tubule rose further."( Clomiphene citrate potentiates the adverse effects of estrogen on rat testis and down-regulates the expression of steroidogenic enzyme genes.
Bharti, S; Misro, MM; Rai, U, 2013
)
0.39
"The above findings indicate that CC in the presence of estrogen synergistically potentiates more adverse effects in testis, inhibiting expression of upstream steroidogenic enzyme genes and leading to disruption of steroidogenesis."( Clomiphene citrate potentiates the adverse effects of estrogen on rat testis and down-regulates the expression of steroidogenic enzyme genes.
Bharti, S; Misro, MM; Rai, U, 2013
)
0.39
" We evaluated the effect of CC on testosterone after 2 weeks, rates of adverse effects and predictors of CC response."( The safety and efficacy of clomiphene citrate in hypoandrogenic and subfertile men.
Aston, KI; Brant, WO; Carrell, DT; Dorais, JA; Hotaling, JM; Johnstone, EB; Myers, JB; Patel, DP; Presson, AP,
)
0.13
"Combination therapy with CC + AZ is an effective and safe alternative for patients with elevated oestradiol level or low testosterone:oestradiol ratio."( Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men.
Alder, NJ; Hotaling, JM; Keihani, S; Myers, JB; Stoddard, GJ, 2018
)
0.48
" There was no significant adverse event in any patient treated with clomiphene citrate."( Long-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism.
Abdullah, N; Chen, X; Costabile, RA; Ells, A; Kavoussi, M; Kavoussi, PK; Krzastek, SC; Machen, GL; Sharma, D; Smith, RP; Sultan, M; Wenzel, JL, 2019
)
0.51
" These data demonstrate that clomiphene citrate is safe and effective with few side effects when used as long-term treatment of hypogonadism."( Long-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism.
Abdullah, N; Chen, X; Costabile, RA; Ells, A; Kavoussi, M; Kavoussi, PK; Krzastek, SC; Machen, GL; Sharma, D; Smith, RP; Sultan, M; Wenzel, JL, 2019
)
0.51
" In this study, we investigated sustained-release clomiphene citrate by using Phosal-based formulation (PBF) and evaluate its decreased side effect on the endometrial receptivity."( Design and evaluation of a novel nanodrug delivery system for reducing the side effects of clomiphene citrate on endometrium.
Aflatoonian, R; Ajdary, M; Amani, A; Amjadi, F; Keyhanfar, F; Mehdizadeh, M; Zandieh, Z, 2020
)
0.56
" For both normal-weight and obese men with low testosterone levels and hypogonadal symptoms, selective estrogen receptor modulators (SERMs), such as clomiphene citrate (CC) and enclomiphene citrate (EC), appear to be effective and safe for improving serum testosterone levels (strength of recommendation [SOR]: C, disease-oriented outcomes from randomized controlled trials [RCTs] and cohort studies)."( Are SERMs safe and effective for the treatment of hypogonadism in men?
Gibbs, LM; Joseph, T; Pham, K, 2022
)
0.91
" Specifically, our aim was to assess any adverse effects of EGCG alone or in combination with an ovarian stimulator on serum liver function tests (LFTs) and folate level."( Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women.
Al-Hendy, A; Christman, GM; Flaminia, A; Flores, VA; González, F; Huang, H; Johnson, JJ; Segars, J; Siblini, H; Singh, B; Taylor, HS; Zhang, H, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters of En in patients with polycystic ovary syndrome were not generally different from the healthy subjects."( Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease.
Ghobadi, C; Ledger, WL; Lennard, MS; Mirhosseini, N; Moghadamnia, A; Rostami-Hodjegan, A; Shiran, MR, 2009
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"Gamete intra-Fallopian transfer (GIFT) was combined with a diagnostic laparoscopy on a routine operating list in a district general hospital."( Gamete intra-fallopian transfer combined with diagnostic laparoscopy: a treatment for infertility in a district hospital.
Bolton, VN; Campbell, S; Pampiglione, JS; Parsons, JH, 1989
)
0.28
"The use of ovulation induction combined with intrauterine insemination (IUI) as a treatment for subfertility in women with patent Fallopian tubes has increased in recent years."( Ovulation induction combined with intrauterine insemination in women 40 years of age and older: is it worthwhile?
Corsan, G; Kemmann, E; Trias, A; Trout, S, 1996
)
0.29
"To compare intrauterine insemination (IUI), direct intraperitoneal insemination (DIPI), and timed-intercourse (TI), each combined with superovulation, in the treatment of couples with unexplained infertility, including couples with minimal endometriosis."( Superovulation combined with insemination or timed intercourse in the treatment of couples with unexplained infertility and minimal endometriosis.
Isaksson, R; Tiitinen, A, 1997
)
0.3
"Superovulation in combination with insemination or intercourse is effective and is still recommended in the treatment of couples with unexplained infertility."( Superovulation combined with insemination or timed intercourse in the treatment of couples with unexplained infertility and minimal endometriosis.
Isaksson, R; Tiitinen, A, 1997
)
0.3
" If treatment with DPPE was begun from the day after tumor inoculation, the inhibitory effect of DPPE was further enhanced, especially when combined with CDDP."( Growth-inhibitory effects of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HCl combined with cisplatin on human ovarian cancer cells inoculated into nude mice.
Hiramatsu, H; Kikuchi, Y; Kita, T; Kudoh, K; Nagata, I; Tode, T, 1997
)
0.3
"We used a single administration of clomiphene citrate (CC), a synthetic oestrogen that is prescribed for infertility treatment, in combination with either a single administration of oestradiol 17beta (E2) or progesterone (P4) to assess the combined effects of these hormones on the uterine surface."( Expression of glucosamine trisaccharides on the rat uterine surface is altered by clomiphene citrate. II. Combination with ovarian hormones.
Dwarte, D; Hosie, M; Murphy, CR; Shaw, T; Terry, V, 2000
)
0.31
"Authors present a case of twin intrauterine pregnancy combined with ectopic pregnancy."( [Successful outcome of an intrauterine twin pregnancy combined with ectopic pregnancy].
Lázár, E; Pálfalvi, L; Petik, D; Sebestyén, A; Siklós, P; Ungár, L, 2000
)
0.31
"A prospective randomized feasibility study was carried out on 10 patients undergoing IVF treatment using a single-dose LHRH antagonist protocol (cetrorelix, Cetrotide) with clomiphene citrate in combination with either human menopausal gonadotrophin (HMG) (n = 5) or recombinant human FSH (rFSH) (n = 5)."( Single dose application of cetrorelix in combination with clomiphene for friendly IVF: results of a feasibility study.
Blanchet, V; Engel, JB; Fanchin, R; Frydman, N; Frydman, R; Le Dû, A; Olivennes, F, 2003
)
0.32
"This study was carried out to determine the pattern of presentation of Polycystic ovary syndrome (PCOS) in patients presenting at our unit and to compare effects of clomiphene alone and in combination with metformin in management of PCOS."( Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin.
Hashmi, SN; Raja, A; Rashid, H; Sultana, N,
)
0.13
"To compare the efficacy of letrozole to recombinant FSH for ovarian stimulation combined with IUI in a group of patients that had failed to conceive after clomiphene citrate (CC) and IUI."( Randomized controlled trial comparing superovulation with letrozole versus recombinant follicle-stimulating hormone combined with intrauterine insemination for couples with unexplained infertility who had failed clomiphene citrate stimulation and intraute
Botsis, D; Creatsas, GK; Gregoriou, O; Konidaris, S; Papadias, K; Vlahos, NF, 2008
)
0.35
"The objective of this study was to test the use of letrozole in combination with follicle-stimulating hormone (FSH) vs clomiphene citrate (CC) with FSH for ovarian hyperstimulation prior to intrauterine insemination (IUI)."( Clomiphene citrate or aromatase inhibitors combined with gonadotropins for superovulation in women undergoing intrauterine insemination: a prospective randomised trial.
Badawy, A; Elnashar, A; Totongy, M, 2010
)
0.36
"To observe the clinical curative effect of Wenshen Yangxue Granule (WSYXG) combined with clomifene citrate (CC) in treating follicular maldevelopment (FM) infertility, and to explore its possible action channels."( [Regulation and control of wenshen yangxue granule combined with clomifene citrate on INH-ACT-FS system in patients with follicular maldevelopment infertility].
Jun-qin, H; Ming-wei, X; Xin-yun, L, 2011
)
0.37
"WSYXG combined with CC could improve Chinese medicine syndrome, regulate the expressions of FM patients' ovary local factors INHB, ACTA and FS, improve the condition of ovary functions, and control the follicle development."( [Regulation and control of wenshen yangxue granule combined with clomifene citrate on INH-ACT-FS system in patients with follicular maldevelopment infertility].
Jun-qin, H; Ming-wei, X; Xin-yun, L, 2011
)
0.37
"To explore the effects of warm needling combined with Zhangmo decoction (see text) on endometrial receptivity in patients with clomiphene (CC)-induced ovulation."( [Effects of warm needling combined with zhangmo decoction on endometrial receptivity in patient with ovulation induction].
Jiang, DS; Wu, XQ; Zhang, YC, 2014
)
0.4
"Warm needing combined with Zhangmo decoction could improve endometrial thickness, morphology and uterine spiral artery to improve pregnancy rate, which has superior effect to clomiphene, clomiphene combined with progynova and clomiphene combined with Zhangmo decoction."( [Effects of warm needling combined with zhangmo decoction on endometrial receptivity in patient with ovulation induction].
Jiang, DS; Wu, XQ; Zhang, YC, 2014
)
0.4
"The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance."( Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance.
Carlomagno, G; Gateva, A; Genazzani, AD; Kamenov, Z; Kolarov, G, 2015
)
0.42
"To evaluate the efficacy of minimal stimulation using discretely administered gonadotropin combined with clomiphene citrate (CC) or letrozole (LTZ) for intrauterine insemination (IUI) cycles."( Minimal stimulation using gonadotropin combined with clomiphene citrate or letrozole for intrauterine insemination.
Cho, S; Choi, YS; Chon, SJ; Kim, SH; Lee, BS; Park, JH; Seo, SK; Yun, BH, 2015
)
0.42
" Each group received human menopausal gonadotropin at a dose of 150 IU by two or three alternative day: CC combined with alternate-day regimen for 2 or 3 days (CC+300, n=37; CC+450, n=89) and LTZ combined with alternate-day regimen for 2 or 3 days (LTZ+300, n=36; LTZ+450, n=95)."( Minimal stimulation using gonadotropin combined with clomiphene citrate or letrozole for intrauterine insemination.
Cho, S; Choi, YS; Chon, SJ; Kim, SH; Lee, BS; Park, JH; Seo, SK; Yun, BH, 2015
)
0.42
"To evaluate time-limited hydrotubation combined with clomiphene citrate as treatment for unexplained infertility."( Time-limited hydrotubation combined with clomiphene citrate treatment for unexplained infertility.
Delibas, IB; Kadanali, S; Karaca, I; Kumtepe, Y; Yapca, OE, 2015
)
0.42
"To observe the therapeutic effect of Qilin Pills combined with clomiphene on idiopathic oligoasthenospermia."( [Qilin Pills combined with clomiphene for idiopathic oligoasthenozoospermia].
Lin, HL; Xu, ZQ; Yang, MG; Zhang, CX; Zheng, GD; Zhuang, ZM, 2015
)
0.42
"We randomly assigned 300 patients with idiopathic oligoasthenospermia to a trial (n = 156) and a control group (n = 144) to be treated with Qilin Pills (6 g, tid) combined with clomiphene (50 mg, qd) and clomiphene alone (50 mg, qd), respectively, both for a course of 12 weeks."( [Qilin Pills combined with clomiphene for idiopathic oligoasthenozoospermia].
Lin, HL; Xu, ZQ; Yang, MG; Zhang, CX; Zheng, GD; Zhuang, ZM, 2015
)
0.42
"Qilin Pills combined with clomiphene can evidently improve the seminal quality and hormone level of oligoasthenospermia patients with no obvious adverse events."( [Qilin Pills combined with clomiphene for idiopathic oligoasthenozoospermia].
Lin, HL; Xu, ZQ; Yang, MG; Zhang, CX; Zheng, GD; Zhuang, ZM, 2015
)
0.42
" The aim of the study was to evaluate the effectiveness and efficacy of letrozole and clomiphene citrate (CC) combined with human menopausal gonadotropin (HMG) in CC-resistant infertile women with PCOS."( Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: a prospective study.
Liu, S; Lu, X; Mao, H; Xi, W; Xue, X; Yang, Y, 2015
)
0.42
"Letrozole in combination with HMG is an effective protocol for reducing the risks of hyperstimulation for ovarian induction in CC-resistant women with PCOS."( Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: a prospective study.
Liu, S; Lu, X; Mao, H; Xi, W; Xue, X; Yang, Y, 2015
)
0.42
"This retrospective study demonstrated the advantages of the use of letrozole over clomiphene citrate in combination with metformin in moderately obese patients with polycystic ovary syndrome who are resistant to stimulation with clomiphene citrate alone."( Comparison of the efficiency of clomiphene citrate and letrozole in combination with metformin in moderately obese clomiphene citrate-resistant polycystic ovarian syndrome patients.
Bjelica, A; Cetković, N; Mladenović-Segedi, L; Petrović, D; Trninić-Pjević, A,
)
0.13
" Especially little is known about efficacy and safety of letrozole (LTZ) combined with low-dose highly purified human menopausal gonadotropin (Hp-HMG) in women with polycystic ovary syndrome (PCOS)."( Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study.
Mueck, AO; Ruan, X; Zhao, Y, 2017
)
0.46
" All patients got LTZ on day 3 for 5 d in combination with Hp-HMG, starting with 75 IU from cycle day 7 and maintained for up to 3 d."( Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study.
Mueck, AO; Ruan, X; Zhao, Y, 2017
)
0.46
"LTZ combined with low-dose Hp-HMG is an effective and safe choice for reducing hyperstimulation and increasing pregnancy rate in CC-resistant women with PCOS."( Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study.
Mueck, AO; Ruan, X; Zhao, Y, 2017
)
0.46
"To investigate the efficacy and safety of the L- and acetyl-L-carnitine complex, vitamins A, E, C, selenium, zinc and other antioxidants ("SpermActin" + "More than vitamins") in combination with clomiphene citrate (CC) in managing male idiopathic infertility in the form of oligo, and/or astheno-, and/or teratozoospermia."( [Using L- and acetyl-L-carnintines in combination with clomiphene citrate and antioxidant complex for treating idiopathic male infertility: a prospective randomized trial].
Bozhedomov, VA; Bozhedomova, GE; Komarina, RA; Lipatova, NA; Rokhlikov, IM; Shcherbakova, EV, 2017
)
0.46
"To observe the effect of electroacupuncture (EA) intervention combined with clomiphene critate (CC) on the blastocyst implantation and pregnancy rate and expression of insulin receptor (INSR) and insulin receptor substrate 1 (IRS 1) proteins in the endometrium in rats with polycystic ovary syndrome (PCOS), so as to reveal its mechanisms underlying improvement of PCOS."( [Electroacupuncture Combined with Clomiphene Promotes Pregnancy and Blastocyst Implantation Possibly by Up-regulating Expression of Insulin Receptor and Insulin Receptor Substrate 1 Proteins in Endometrium in Rats with PCOS].
Lai, MH; Ma, HX; Song, XH, 2016
)
0.43
"The aim of this work was to investigate the value of laparoscopic ovarian drilling (LOD) compared with GnRH antagonist flexible protocol combined with cabergoline (Cb), as a prophylaxis against the re-development of ovarian hyperstimulation syndrome (OHSS) in women with clomiphene citrate-resistant polycystic ovary disease (CCR-PCOD) who had severe OHSS before in a previous ICSI cycle."( Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
Hefzy, E; Seyam, E, 2018
)
0.48
"Objective To observe the clinical effects of Bushen Quyu Recipe (BQR) combined with acupuncture in treatment of clomiphene-resistant polycystic ovary syndrome (PCOS) infertility pa- tients after cold needle puncture drainage operation."( [Clinical Effect of Bushen Quyu Recipe Combined with Acupuncture in Treatment of Clomiphene- resistant Polycystic Ovary Syndrome Infertility Patients after Cold Needle Puncture Drainage Operation].
Liu, X; Mo, WW; Ruan, HB; Wang, MZ; Wu, TT, 2016
)
0.43
"In view of the high incidence of polycystic ovary syndrome (PCOS) and the unsatisfactory therapeutic effects of dimethyldiguanide or clomifene citrate alone, our study aimed to investigate the therapeutic effects of dimethyldiguanide combined with clomifene citrate in the treatment of PCOS."( Therapeutic effects of dimethyldiguanide combined with clomifene citrate in the treatment of polycystic ovary syndrome.
Gao, S; Jiang, J; Zhang, Y, 2019
)
0.51
" Patients in group A were treated with dimethyldiguanide combined with clomifene citrate, while patients in group B were treated with clomifene citrate alone."( Therapeutic effects of dimethyldiguanide combined with clomifene citrate in the treatment of polycystic ovary syndrome.
Gao, S; Jiang, J; Zhang, Y, 2019
)
0.51
"To study the effect of Compound Amino Acid Capsules (CAAC) combined with clomiphene in the treatment of severe oligospermia."( [Compound Amino Acid Capsules combined with clomiphene for severe oligospermia].
Bao, YG; Dai, XW; Wu, GJ; Zheng, LW, 2019
)
0.51
"A total of 104 patients with severe oligospermia admitted to our Center of Reproductive Medicine from January to September 2018 were randomly assigned to a trial (n = 60) and a control group (n = 44), the former treated by oral administration of CAAC combined with clomiphene and the latter with clomiphene only, both for 12 weeks."( [Compound Amino Acid Capsules combined with clomiphene for severe oligospermia].
Bao, YG; Dai, XW; Wu, GJ; Zheng, LW, 2019
)
0.51
"CAAC combined with clomiphene can significantly improve the semen parameters of the patients with severe oligospermia, with no obvious adverse events."( [Compound Amino Acid Capsules combined with clomiphene for severe oligospermia].
Bao, YG; Dai, XW; Wu, GJ; Zheng, LW, 2019
)
0.51
"This was a single center, parallel-groups, double-blind, and placebo-controlled randomized trial involving 186 eligible women undergoing induction of ovulation with clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily starting from the third day of menstrual cycle and for 5 days combined with either oral Vitamin D (ossofortin®, EVA PHARMA) 10,000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries) 1250 mg twice daily or to receive a placebo with calcium for three successive induction cycles."( The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial.
Elkholy, A; Rasheedy, R; Salim, Y; Sammour, H, 2020
)
0.56
"Although several clinical trials have compared the clinical efficacy of clomiphene citrate (CC) combined with metformin (MET) in the treatment of women with polycystic ovary syndrome (PCOS), the results are controversial."( Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome.
Chen, X; Diao, W; Feng, J; Lin, W; Ma, P; Zhou, H, 2022
)
0.72
"CC combined with MET has an advantage in improving the clinical pregnancy rate compared to CC alone; however, there is no significant difference in the rate of ovulation."( Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome.
Chen, X; Diao, W; Feng, J; Lin, W; Ma, P; Zhou, H, 2022
)
0.72
"Clinical efficacy of Fuke Qianjin tablets combined with clomiphene citrate on infertility patients with polycystic ovary syndrome (PCOS) was expected to be retrospectively analyzed in this study."( The efficacy of Fuke Qianjin tablets combined with clomiphene citrate on infertility patients with polycystic ovary syndrome: A retrospective analysis.
Cao, S; Ge, X; Hu, SH; Li, LH; Li, YX; Liang, JX; Zhang, Y, 2023
)
0.91
"After a variety of comparisons and analyses, Fuke Qianjin tablets combined with clomiphene citrate were confirmed to improve the uterine receptivity and ovarian status, levels of sex hormone, inflammation and oxidative stress, and pregnancy outcomes in infertility patients with PCOS."( The efficacy of Fuke Qianjin tablets combined with clomiphene citrate on infertility patients with polycystic ovary syndrome: A retrospective analysis.
Cao, S; Ge, X; Hu, SH; Li, LH; Li, YX; Liang, JX; Zhang, Y, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The enhancement was not due to increased bioavailability because cellular uptake of [3H]tamoxifen was not increased and the lipoprotein fraction of serum had negligible [3H]tamoxifen-binding capacity."( Cytostatic effect of antiestrogens in lymphoid cells: relationship to high affinity antiestrogen-binding sites and cholesterol.
Kon, OL; Ng, ML; Sim, KY; Tang, BL; Teo, CC, 1989
)
0.28
"Combined rosiglitazone and clomiphene was an effective therapeutic regimen for correcting insulin resistance in patients with PCOS, possibly by reducing IGF1 bioavailability to the ovaries, thus modifying the hyperandrogenic intrafollicular milieu that occurs in PCOS."( Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.
Shaarawy, M; Shobokshi, A, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Conception occurred in the first cycle after increasing drug dosage or the addition of human chorionic gonadotrophin (HCG) to the treatment regimen."( An hypothesis for high multiple pregnancies after clomiphene.
Burger, HG; Healy, DL, 1978
)
0.26
"Radioimmunological methods have been used to assay the plasma concentrations of gonadotropins, androgens (expressed as the sum of testosterone and dihydrotestosterone) and 17beta-oestradiol in 98 patients suffering from dysspermia of variable etiology, after stimulation with GnRH, Clomiphene, L-Dopa, Cyclophenyl, HCG in various dosage schemes, and HMG."( [Dynamic tests with GnRH, L-dopa, clomiphene, cyclophenyl, HCG and HMG in 98 cases of dysspermia due to a variety of causes].
De Aloysio, D; Farello, P; Flamigni, C; Fronticelli, A; Nardi, M; Venturoli, S, 1977
)
0.26
" 100 mg of clomiphene citrate was given daily for 7 days (the dosage of clomiphene varied somewhat with history of preexisting conditions)."( Dynamic testing of hypothalamic-pituitary function in abnormalities of ovulation.
Jones, GE; Rosenwaks, Z; Shoemaker, J; Wentz, AC, 1977
)
0.26
" Even at the lower dosage used, EE2 decreased drastically the levels of LH but less completely that of FSH."( [Effects of clomiphene and estrogens on circulating gonadotropins, testosterone, androstenedione, in old menopausal women (author's transl)].
Bertrand, J; de Peretti, E; Forest, MG; Pugeat, M; Tourniaire, J, 1977
)
0.26
"Clomiphene (Dyneric) in a daily dosage of 100--300 mg, partially combined with HCG (n = 12), was used in the treatment of 86 women aged 19 to 39 years with primary or secondary infertility of endocrine origin in 296 menstrual cycles."( [Treatment with clomiphene of endocrine primary and secondary infertility in women (author's transl)].
Plenefisch, A; Schindler, AE, 1979
)
0.26
" In the later stages of pregnancy, an increase in the dosage of vasopressin was necessary to achieve a satisfactory control of the symptoms of diabetes insipidus."( Clomiphene-induced pregnancy in a patient with diabetes insipidus and hypothyroidism.
Ahmad, Z; Chelvam, P, 1979
)
0.26
"A review of recent experience with clomiphene citrate at the Yale-New Haven Medical Center yields the following conclusions: 1) Clomiphene citrate administered at high doses (150 mg and 200 mg) is effective in inducing ovulation in women who would otherwise have failed to conceive if treatment were restricted to only lower dosage regimens."( Ovulation and pregnancy rates with clomiphene citrate.
Gorlitsky, GA; Kase, NG; Speroff, L, 1978
)
0.26
" Of the 11 patients in the group with secondary amenorrhea who had a "positive" response to LH-RH, 7 ovulated at a dose of 150 mg (or less) of clomiphene citrate, while only 1 of the 11 patients with a "negative" response ovulated while receiving a similar dosage of clomiphene."( The relationship between the pituitary response to luteinizing hormone-releasing hormone and the ovulatory response to clomiphene citrate.
Feore, JC; Taymor, ML, 1976
)
0.26
" The effect of varying the dosage of injected E2 (0."( Different nuclear binding sites for antiestrogen and estrogen receptor complexes.
Baudendistel, LJ; Ruh, TS, 1977
)
0.26
" Ovarian over-stimulation was directly related to the dosage of clomiphene, and the increased levels of 17 alpha-hydroxyprogesterone thus produced persisted into the seventh week of pregnancy."( Corpus luteum function during pregnancies of previously infertile women.
Gentry, WC; Karow, WG, 1976
)
0.26
" It is suggested that this production of a multiple ovulation in a woman with luteal deficiency be the result of excessive dosage of Clomid."( Triplet pregnancy in a subfertile woman treated with clomiphene citrate.
Pezzani, M, 1976
)
0.26
" Duration and dosage can be determined on the basis of daily plasma estrogen levels."( Plasma estrogen monitoring of ovulation induction.
Wu, CH, 1975
)
0.25
" The dosage was in the first course of treatment 50 mg daily."( [Treatment of anovulatory sterility using clomiphen].
Lisse, K, 1975
)
0.25
" Increased clomiphene dosage resulted in higher plasma oestradiol and progesterone levels."( Plasma oestradiol and progesterone estimation for the monitoring of induction of ovulation with clomiphene and chorionic gonadotrophin.
Mcgarrigle, HH; Radwanska, E; Swyer, GI, 1975
)
0.25
" The protocols involve dosing rats with CC during, and evaluation of multiple endpoints following, (a) the first 8 days of pregnancy; (b) early pseudopregnancy, accompanied by decidual induction; and (c) the pre- and postimplantation intervals of early pregnancy."( Validation of protocols for assessing early pregnancy failure in the rat: clomiphene citrate.
Cummings, AM; Harris, ST; Perreault, SD, 1991
)
0.28
" Intramuscular injections of growth hormone (24 IU) or placebo were given on alternate days concurrently with the same daily dosage of gonadotrophin as administered in the patient's pretreatment cycle."( Co-treatment with growth hormone of sub-optimal responders in IVF-ET.
Jacobs, HS; Mason, BA; Owen, EJ; West, C, 1991
)
0.28
" The administered dosage ranged from 50 to 250 mg/d."( Comparison of five clomiphene citrate dosage regimens: follicular recruitment and distribution in the human ovary.
Blankstein, J; Goldenberg, M; Kukia, E; Lewinthal, D; Mashiach, S; Shalev, J; Tepper, R, 1989
)
0.28
"Two groups, each of ten female rats, were orally dosed with the synthetic oestrogens diethylstilboestrol (DES; 6 mg/kg day) and hexoestrol (60 mg/kg/day) for 6 wk."( Subacute toxicity of diethylstilboestrol and hexoestrol in the female rat, and the effects of clomiphene pretreatment.
Hart, JE, 1988
)
0.27
" Pregnant and nonpregnant patients were compared with regard to their age, the total dosage of hMG, the cycle day at oocyte retrieval, the E2 levels 48 and 24 hours before laparoscopy, the E2 rise, the number of retrieved oocytes, and the cleavage rate."( Factors influencing successful in vitro fertilization and embryo transfer: a matched pair study.
Deutinger, J; Fischl, F; Janisch, H; Müller-Tyl, E; Reinthaller, A; Riss, P, 1986
)
0.27
" This dosage is continued until the leading follicle reaches a diameter of 14 mm."( [Ovulation induction for in vitro fertilisation at the Tygerberg Hospital].
Kruger, TF; Lombard, CJ; Muller, LM; van der Merwe, JP, 1987
)
0.27
" At higher E2- or AE-concentrations this positive effect was lost, resulting in bell shaped dose-response curves."( Effects of estradiol and some antiestrogens (clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture.
Emons, G; Knuppen, R; Ortmann, O; Thiessen, S, 1986
)
0.27
"The present study was designed to investigate the dose-response of clomiphene on several estrogenic responses in the immature rat uterus and to compare it to available data on estradiol-17 beta."( The estrogenic responses to clomiphene in the different cell types of the rat uterus: morphometrical evaluation.
Grunert, G; Neumann, G; Porcia, M; Tchernitchin, AN, 1987
)
0.27
" This became more clearly apparent when cells were treated with the 4-hydroxylated derivatives of these compounds where, because of enhanced affinity for the oestrogen receptor (ER), the dose-response curves for the two components could be separated."( Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells.
Hall, RE; Ruenitz, PC; Sutherland, RL; Watts, CK, 1987
)
0.27
" The optimum dosage to induce ovulation ranged between 10 and 20 micrograms per pulse at a frequency of 60 to 90 minutes."( Ovulation induction in clomiphene nonresponsive patients: the place of pulsatile gonadotropin-releasing hormone in clinical practice.
Glass, MR; Hancock, KW; Molloy, BG, 1985
)
0.27
"Despite the increasing use of clomiphene citrate (CC) in normally cycling women undergoing in vitro fertilization, comprehensive data on the dose-response effects of the drug are unavailable."( A comprehensive dose-response study of clomiphene citrate for enhancement of the primate ovarian/menstrual cycle.
Hodgen, GD; Littman, BA, 1985
)
0.27
" Based on the size and number of follicles, the peripheral levels of estradiol, and the rate of follicular growth and increase in estradiol, human menopausal gonadotropin was continued at a dosage of 1 to 3 ampules/day through the day of human chorionic gonadotropin administration."( Preliminary experience with a combination of clomiphene and variable dosages of menopausal gonadotropins for enhanced follicular recruitment.
Beauchamp, PJ; Berkowitz, AS; Maklad, NF; Quigley, MM; Schmidt, CL; Wolf, DP, 1985
)
0.27
" One patient demonstrated hyperstimulation, with large increments of estradiol and the development of multiple follicles, similar to what occurred with a larger dosage of GnRH alone."( Potentiation of GnRH response by clomiphene citrate.
Corenblum, B; Goerzen, J; Taylor, PJ, 1985
)
0.27
", Cincinnati, OH), using the same dosage regimen of CC (150 mg/day for days 3 to 7 of the cycle)."( Comparison of two brands of clomiphene citrate for stimulation of follicular development in a program for in vitro fertilization.
Diamond, MP; Herbert, CM; Maxson, WS; Wentz, AC, 1986
)
0.27
" These assays are also important in determining proper dosage for gonadotrophin and clomiphene treatment."( Oestrogen assays in gynaecology.
Brown, JB, 1974
)
0.25
"Enlargement of an atrophic testis occurred in an oligospermic patient during long-term therapy with a low dosage of cisclomiphene."( Development of a testicular tumour during cisclomiphene therapy.
Faiman, C; Reyes, FI, 1973
)
0.25
"Ponderal, histological, and biochemical responses of the uterus, cervix, and vagina to the same dosage (1."( Studies on physiology & biochemistry of female genital tract: response of uterus, cervix & vagina of albino rats to cis- & trans-clomiphene in the presence or absence of estrogen.
Karkun, JN; Mehrotra, PK, 1973
)
0.25
" Changes in the results of the tests were found to be related to the dosage and, above all, to the date on which treatment is started."( [Study of the basal temperature, cervix mucus, vaginal cytology, spermatic penetration, and length of the menstrual cycle, in patients under clomiphene treatment].
Bailón Uriza, R; Conde, BI; Ruiz Velasco, V; Salas, E, 1969
)
0.25
" Dose-response curves for the purifed LH, an impure urinary LH preparation, pituitary powder, and LH in plasma were all identical."( Radioimmunoassay for luteinizing hormone in human plasma or serum: physiological studies.
Odell, WD; Rayford, PL; Ross, GT, 1967
)
0.25
" Doubling the clomiphene dosage made no significant difference to any of the parameters examined."( The effect of clomiphene and conjugated oestrogens on cervical mucus.
van der Merwe, JV, 1981
)
0.26
"Either to induce ovulation in anovulatory infertility patients or to enhance ovulation in patients with mild endometriosis or luteal phase inadequacy, we utilized a sequential regimen of low-dose clomiphene citrate (CC) followed by human menopausal gonadotropin (hMG) injections on alternate days; duration and dosage of menotropin therapy was individualized by using serum estradiol levels for monitoring until the time of administration of human chorionic gonadotropins."( Sequential clomiphene citrate-menotropin therapy for induction or enhancement of ovulation.
Jones, JR; Kemmann, E, 1983
)
0.27
"When clomiphene citrate is used for enhanced follicular recruitment in an in vitro fertilization and embryo transfer program, the usual dosage is 150 mg/day, although we recently reported comparable follicular development (size and number) with 50 mg/day."( Clomiphene citrate in an in vitro fertilization program: hormonal comparisons between 50- and 150-mg daily dosages.
Berkowitz, AS; Gilbert, SA; Quigley, MM; Wolf, DP, 1984
)
0.27
" In order to analyze our results, we divided our patients into seven groups, according to the largest dosage of clomiphene citrate received."( Progressive dosages of clomiphene in hypothalamic anovulation.
García-Flores, RF; Vázquez-Méndez, J, 1984
)
0.27
" In each experiment, 20 hens, selected as broody from commercial breeding flocks, were treated; half were treated with CC at a dosage of 6 mg/kg body weight/day (per os) for 5 consecutive days, and the rest (control) received parallel treatment with a placebo (CaCO3)."( The effect of clomiphene-citrate on broody turkey hens.
Perek, M; Robinzon, B; Shafir, Z; Snapir, N, 1984
)
0.27
" Increasing the clomiphene citrate dosage was unsuccessful in improving endometrial maturation."( Induction of luteal phase defect with clomiphene citrate.
Cook, CL; Sanfilippo, JS; Schroeder, JA; Yussman, MA, 1984
)
0.27
" Clomiphene given in this dosage seems to be safe for periods of up to 15 months and appears to be a rational and useful agent for the treatment of this patient group."( Clomiphene treatment of the idiopathic hypofertile male: high-dose, alternate-day therapy.
Auletta, F; Kandel, GL; Prinz, LM; Ross, LS, 1980
)
0.26
" These patterns allow a good diagnostic presumption before the following missing menses, which can be useful when dealing with women treated for infertility and when plasmatic dosage of hCG or beta hCG cannot be rapidly available."( [Urinary estrone and estradiol levels in the diagnostic presumption of pregnancy (author's transl)].
Chikhaoui, Y; Crastes de Paulet, A; Cristol, P; Descomps, B; Durand, G; Hedon, B; Viala, JL, 1980
)
0.26
" Clomiphene was given continuously with dosage increments every 5 days, up to a maximum dose of 3750 mg, and ovarian response was monitored with urinary estrogen estimation and with ultrasound."( Incremental clomiphene therapy: a new method for treating persistent anovulation.
Brown, JB; McBain, JC; O'Herlihy, C; Pepperell, RJ; Sandri, L; Smith, MA, 1981
)
0.26
"Forty-nine patients in whom clomiphene citrate failed to induce ovulation were treated for 177 cycles with a fixed low dosage of menotropin."( A life-table analysis of pregnancy yield in fixed low-dose menotropin therapy for patients in whom clomiphene citrate failed to induce ovulation.
Goldfarb, AF; Mansi, ML; Schlaff, S, 1982
)
0.26
" The increased incidence of twinning appears to be related to the type and dosage of medication used, and the patient's underlying problem."( Twin pregnancies following induction of ovulation: a literature review.
Lamont, JA, 1982
)
0.26
" The determination of follicle size and number by ultrasound scan during ovulation induction by the routinely used starting dosage of clomiphene has revealed a previously unrecognized incidence of ovarian overstimulation, and may allow the rationalization of ovulation induction regimens."( Effects of clomiphene administration on ovarian function as measured by estradiol and ultrasound.
Grudzinskas, JG; Picker, RH; Saunders, DM; Sinosich, MJ; Smith, DH, 1983
)
0.27
" The dosage of clomiphene was 100 mg per day for 5 days."( [Results of treatment of functional sterility with clomifen].
Hofmann, R; Martens, E; Rudolf, K; Rüting, M, 1983
)
0.27
" Increase in the endometrial glycogen content in the clomiphene cycle was accompanied by a corresponding increase of the dosage of clomiphene."( A graduated regimen of clomiphene citrate: its correlation to glycogen content of the endometrium and serum levels of estradiol and progesterone in infertile patients at the midluteal phase.
Fukuma, K; Fukushima, T; Maeyama, M; Matsuo, I; Mimori, H, 1983
)
0.27
" This study examines whether a reduced dosage of CC will induce the maturation of a similar number of follicles."( Comparison of two clomiphene citrate dosage regimens for follicular recruitment in an in vitro fertilization program.
Maklad, NF; Quigley, MM; Wolf, DP, 1983
)
0.27
"Sixty-nine infertile women with a midluteal serum progesterone level of 4 to 14 ng/ml were treated with a graduated dosage schedule of clomiphene citrate until the progesterone level on day 21 was greater than 20 ng/ml."( Clomiphene citrate therapy of infertile women with low luteal phase progesterone levels.
Hammond, MG; Talbert, LM, 1982
)
0.26
" Among the women who felt improvement, 85% responded to the 250 mg/cycle dosage and 15% required the 350 mg/cycle dosage."( Menorrhagia associated with the wearing of IUD--the results of treatment with clomiphene citrate.
Bahari, CM; Gorodesky, IG; Neri, A; Schachter, A, 1982
)
0.26
" We conclude that exogenous EE, in the dosage used in this study, does not overcome CC-induced alterations in endometrial thickness."( Exogenous estrogen therapy concurrent with clomiphene citrate--lack of effect on serum sex hormone levels and endometrial thickness.
Battino, S; Ben-Ami, M; Geslevich, Y; Matilsky, M; Shalev, E; Weiner, E, 1994
)
0.29
"To determine the effect of clomiphene citrate (CC) and hMG on cervical mucus (CM), optimally sampled in the periovulatory period from confirmed ovulatory cycles, in the dosage range commonly employed for ovulation induction."( The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles.
Buyalos, RP; Gelety, TJ, 1993
)
0.29
" Thus, under dosing conditions commonly used to assess uterotrophic activity, these "antiestrogens" are complete, albeit less potent, estrogen agonists in the luminal epithelium and, unlike estrogens, induce hypertrophy in the glandular epithelium."( Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens.
Branham, WS; Sheehan, DM; Zehr, DR, 1993
)
0.29
"We monitored the follicular growth ultrasonographically from the eighth day of the menstrual cycle, and assessed E2 and LH daily dosage from the tenth day."( Induction of multifollicular growth in patients non responding to clomiphene citrate and gonadotropins or gonadotropins only.
Diaferia, A; Loizzi, P; Nicastri, PL; Tartagni, M, 1995
)
0.29
" Dosage is standardised on a mg/kg basis."( In vitro fertilisation. A review of drug therapy and clinical management.
Jennings, JC; Moreland, K; Peterson, CM, 1996
)
0.29
" In order to determine whether CLO has tissue selective actions, we performed a dose-response study in adult (6-month-old) ovariectomized (OVX'd) rats."( Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats.
Bryant, HU; Jimenez, MA; Magee, DE; Turner, RT, 1997
)
0.3
"All patients received individualized dosing of hMG after 5 days of CC."( Sonographic assessment of endometrial pattern and thickness in patients treated with clomiphene citrate, human menopausal gonadotropins, and intrauterine insemination.
Ananth, CV; Bohrer, MK; Hock, DL; Kemmann, E, 1997
)
0.3
"6 mg/kg of MDL 103,323 did not further increase BMD or bone strength, indicating a bell-shaped dose-response curve."( The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats.
Ammann, P; Bonjour, JP; Bourrin, S; Brunner, F; Meyer, JM; Rizzoli, R, 1999
)
0.3
" Plasma levels of insulin and glucose were measured after a 75-g glucose load, and CC was given at a dosage of 50-250 mg/d for ovulation-induction."( Growth hormone response to clonidine in anovulatory infertile women resistant to clomiphene citrate stimulation.
Garrone, S; Minuto, F; Ragni, N; Rossato, P, 2000
)
0.31
" experimental newborn rats were given clomphene citrate subcutaneously in a dosage of 100 mg/kg/day for five days."( Effects of clomiphene citrate on neonatal rat skin.
Deveci, E; Inalöz, HS; Inalöz, SS; Unal, B, 2000
)
0.31
"Nineteen of 48 (40%) patients resumed spontaneous menses following treatment and showed presumptive evidence of ovulation with metformin alone; 15/48 (31%) required CC (50 mg) in conjunction with metformin therapy, and 10 of these 15 (67%) had evidence of ovulation; 20/48 (42%) conceived with a median time to conception of 3 months, and 7 of these 20 (35%) had spontaneous abortions (SAB); 19/48 (40%) had gastrointestinal-related side effects, and 5 of 48 patients (10%) had to decrease the dosage of metformin."( Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome.
Buster, JE; Carson, SA; Heard, MJ; Pierce, A, 2002
)
0.31
" In the remaining non-CC resistant metformin failure cases the dosage of metformin was incrersed to 500 mg three times daily for investigating menstrual cycle."( [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Huang, Z; Li, J; Shen, H; Song, J; Zhang, Y, 2002
)
0.31
" In others 6 metformin failure cases the dosage of metformin was increased to 500 mg three times daily, one restored menstrual cycle and became pregnant."( [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Huang, Z; Li, J; Shen, H; Song, J; Zhang, Y, 2002
)
0.31
" However, a significant proportion of women with PCOS fail to ovulate with the use of standard dosage of CC and are called CC-resistant PCOS."( Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome.
Abd el-Aal, G; Abdel-Kareem, O; Amin, M; Maruo, T; Moriyama, T; Takekida, S, 2003
)
0.32
" The treated grop was treated with the combination therapy and the control group treated by the same dosage of clomiphene alone."( [Clinical observation on treatment of Stein-Leventhal syndrome caused sterility by combined use of clomiphene and Chinese nourishing shen and activating blood circulation drugs].
Cai, JF; Lang, FJ; Shao, RY, 2004
)
0.32
"The dose-response relationship of clomiphene was established from a meta-analysis of data from 13 published reports."( Monitoring plasma concentrations to individualize treatment with clomiphene citrate.
Ledger, WL; Lennard, MS; Rostami-Hodjegan, A; Tucker, GT, 2004
)
0.32
"A fixed-dosage regimen of 50 mg clomiphene per day is likely to cause ovulation in only 46% of patients; subsequent increment in dosage increases the number of responders but at the expense of considerable delay in individualization of treatment."( Monitoring plasma concentrations to individualize treatment with clomiphene citrate.
Ledger, WL; Lennard, MS; Rostami-Hodjegan, A; Tucker, GT, 2004
)
0.32
"07 for gonadotrophins, and no substantial relationships to dosage or cycles of use."( Breast cancer risk associated with ovulation-stimulating drugs.
Althuis, MD; Brinton, LA; Lamb, EJ; Mabie, JE; Moghissi, KS; Scoccia, B; Westhoff, CL, 2004
)
0.32
" Ovarian response was represented by the number of oocytes, serum estradiol, the duration and dosage of gonadotrophins."( Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment.
Chan, CC; Ho, PC; Ng, EH; Tang, OS, 2005
)
0.33
" Both basal AFC and combined FSH concentration were predictive factors of serum estradiol concentration, whereas stimulated FSH concentration was predictive of the total dosage of gonadotrophins."( Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment.
Chan, CC; Ho, PC; Ng, EH; Tang, OS, 2005
)
0.33
" Median adherence for both metformin and clomiphene citrate tablets was within acceptable limits and unrelated to ovulation: thus, failure to comply with physician recommendations for metformin dosing was not the reason for low ovulation and pregnancy rates in the PPCOS Trial."( Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial.
Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, G; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2008
)
0.35
" A FSH dosage nomogram was constructed based on these parameters."( Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate.
Arce, JC; Balen, A; Devroey, P; Helmgaard, L; Nyboe Andersen, A; Platteau, P, 2008
)
0.35
"To compare the effect on follicular growth and endocrine parameters of follicular phase administration of anastrozole to healthy, normoovulatory women in doses of 1 or 5 mg, respectively, with the conventional dosing regimen for ovulation induction with clomiphene citrate (CC)."( Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison.
Diedrich, K; Griesinger, G; Schröer, A; Schultze-Mosgau, A; von Otte, S, 2009
)
0.35
" When serum prolactin was controlled at normal levels, we decreased the dosage of bromocriptine step by step (1."( [Analysis of therapeutic outcomes of polycystic ovary syndrome patients with hyperprolactinemia].
Chen, ZJ; Gao, Q; Liu, H; Ma, ZX; Sheng, Y; Shi, YH; Yan, JH, 2008
)
0.35
"Bromocriptine administration before the stimulated ovulation therapy can decrease the total dosage and treatment course of ovulating drugs."( [Analysis of therapeutic outcomes of polycystic ovary syndrome patients with hyperprolactinemia].
Chen, ZJ; Gao, Q; Liu, H; Ma, ZX; Sheng, Y; Shi, YH; Yan, JH, 2008
)
0.35
" Mechanisms for multiple pregnancy include dosing variation, adjuvant therapies, pretreatment weight loss and a cumulative effect of multiple clomiphene cycles."( Clomiphene ovulation induction and higher-order multiple pregnancy.
Kroon, B; McDowell, S; Yazdani, A, 2013
)
0.39
" Demographic and endocrine characteristics, the total number of oocytes retrieved, cancellation rate and clinical pregnancy rate were collected Results: Total dosage of gonadotropins (p=0."( The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients.
Bakacak, M; Ficicioglu, C; Kaspar, C; Kizilkale, O; Ozcan Cenksoy, P; Suhha Bostanci, M; Yesiladali, M, 2014
)
0.4
" The mean ovarian dysplasia score was significantly higher in the tamoxifen group whatever the dosage (p = 0."( Morphological and immunohistochemical analysis in ovaries and fallopian tubes of tamoxifen, letrozole and clomiphene-treated rats.
Chene, G; Clemenson, A; Lacoste, CR; Lecointre, R; Lima, S; Peoc'h, M; Trombert, B, 2014
)
0.4
" In the stair-step protocol,patients were treated with CC 50 mg/day for 5 days and then in nonresponsive patients, the dosage was increased to 100 mg/day for 5 days in the same cycle."( Clomiphene citrate 'stair-step' protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial.
Demir, B; Deveci, CD; Dilbaz, B; Goktolga, U; Sengul, O, 2015
)
0.42
"To determine, in a chronic dosing study, the oral toxicity potential of the test substances, enclomiphene citrate (ENC) and zuclomiphene citrate (ZUC), when administered to male mice by oral gavage."( Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice.
Fontenot, GK; Podolski, JS; Wiehle, RD, 2016
)
0.65
"In this chronic dosing study in mice, profound effects on Leydig cells, epididymis, seminal vesicles, and kidneys were seen, as well as effects on serum testosterone, follicle-stimulating hormone and luteinising hormone levels that were associated with ZUC treatment only."( Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice.
Fontenot, GK; Podolski, JS; Wiehle, RD, 2016
)
0.43
" Gonadotropin cycle characteristics including dosing and duration of treatment, follicular recruitment, peak estradiol levels, and endometrial lining thickness differed between certain groups."( Racial Disparities in Fertility Care: an Analysis of 4537 Intrauterine Insemination Cycles.
Batsis, M; Dimitriadis, I; Petrozza, JC; Souter, I, 2017
)
0.46
" Our study has shown that in the phenotype 2 examined, ovarian volume did not have any predictive value of the dosage required to induce ovulation."( Ovarian volume and PCOS: a controversial issue.
Bifulco, G; Bruzzese, D; De Rosa, N; Della Corte, L; Giampaolino, P; Mercorio, A, 2018
)
0.48
" Although increasing the dosage of gonadotropins for ovarian hyper stimulation treatment in patients with poor ovarian response is beneficial with respect to retrieved oocytes, meiosis II oocytes and number of embryos, the increased dosage does not provide a statistically significant increase in clinical pregnancy rates."( A comparison of treatment results of the different treatment protocols in patients with poor ovarian response.
Bilgic, BE; Incebiyik, A; Kutlu, HT; Sanverdi, I, 2018
)
0.48
"The use of long protocol during controlled ovarian stimulation for assisted reproduction attracts high dosage of gonadotropins."( Low dose clomiphene citrate as a mild stimulation protocol in women with unsuspected poor in vitro fertilization result can generate more oocytes with optimal cumulative pregnancy rate.
Cui, YG; Li, X; Liu, J; Ma, X; Meng, Y; Ochin, H; Shen, J; Song, J; Wang, L, 2018
)
0.48
"For patients with POR, controlled ovarian stimulation protocols using adjuvant treatment with DHEA, CoQ10 and GH showed better clinical outcomes in terms of achieving pregnancy, and a lower dosage of gonadotrophin required for ovulation induction."( Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis.
Chang, HM; Guo, J; Huang, H; Leung, PCK; Sheng, JZ; Shu, J; Zhang, C; Zhang, Y, 2020
)
0.56
" It was interesting that dosage of HMG were significant lower in group B compared with those in group A and group C (P<0."( Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study.
Chen, J; Chi, L; Guo, Q; Hu, RK; Pei, YH; Ren, QL; Tan, Y, 2020
)
0.56
"A short-term supplementation of vitamin E can improve oxidative stress, and reduce exogenous HMG dosage to lower the economic cost with a similar pregnancy rate in the ovulation induction cycle."( Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study.
Chen, J; Chi, L; Guo, Q; Hu, RK; Pei, YH; Ren, QL; Tan, Y, 2020
)
0.56
"The increased risk of idiopathic generalized epilepsy may be due to confounding from time stable parental characteristics related to treatment with clomiphene citrate, since the association was strongest with the lowest administered dosage of clomiphene citrate prior to conception, and the association disappeared in a sibling analysis."( Fertility treatment with clomiphene citrate and childhood epilepsy: a nationwide cohort study.
Henriksen, TB; Kesmodel, US; Kettner, LO; Matthiesen, NB; Ramlau-Hansen, CH, 2021
)
0.62
"The increased risk of focal epilepsy may be related to the hormonal treatment, since the association tended to increase with increasing cumulative dosage of clomiphene citrate prior to conception, and the association persisted in a sibling analysis."( Fertility treatment with clomiphene citrate and childhood epilepsy: a nationwide cohort study.
Henriksen, TB; Kesmodel, US; Kettner, LO; Matthiesen, NB; Ramlau-Hansen, CH, 2021
)
0.62
" CC was applied in a dosage of 25mcg per day, starting on cycle day 7 until ovulation trigger day."( Low-dose clomiphene citrate does not reduce implantation and live birth rates in otherwise unstimulated modified natural cycle IVF-retrospective cohort study.
Grädel, F; Kohl Schwartz, AS; Mitter, VR; von Wolff, M, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency10.33030.044717.8581100.0000AID485294; AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency12.58933.981127.764939.8107AID504842
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency28.18380.00527.809829.0929AID588855
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency22.38720.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency23.10930.005210.865235.4813AID686970
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency35.48130.010323.856763.0957AID2662
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.95260.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency14.80510.004611.374133.4983AID624296; AID624297
Alpha-synucleinHomo sapiens (human)Potency31.62280.56239.398525.1189AID652106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ubiquitin-conjugating enzyme E2 NHomo sapiens (human)IC50 (µMol)20.00000.873010.721978.4000AID493155
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)1.27200.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.66600.00000.887110.0000AID625218
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)1.05000.00000.536910.0000AID625184
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.00460.00000.723732.7000AID625258
Estrogen receptorHomo sapiens (human)Ki0.00130.00000.42297.9070AID625258
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)1.66900.00010.545310.0000AID625186
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)2.51300.00021.67898.6800AID625185
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.86200.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.85500.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)3.62800.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki1.29000.00000.690210.0000AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)1.65100.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.23000.00000.79519.1201AID625154
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)1.77100.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki1.27200.00000.72926.9183AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.93600.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.35100.00010.807410.0000AID625201
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)5.35000.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki3.02400.00000.930610.0000AID625196
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)10.00000.00002.015110.0000AID625249
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)1.62800.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.39200.00000.59729.1201AID625151
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)5.67300.00233.24158.0600AID625206
Beta-3 adrenergic receptorHomo sapiens (human)Ki4.25400.00302.30986.0450AID625206
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)5.35000.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki3.02400.00010.949010.0000AID625196
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)1.57800.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.72100.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)1.48200.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.21500.00030.483410.0000AID625203
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)2.07100.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.43900.00000.54057.7600AID625153
Substance-K receptorHomo sapiens (human)IC50 (µMol)4.52500.00013.12109.5530AID625227
Substance-K receptorHomo sapiens (human)Ki1.50800.00011.92429.7930AID625227
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)0.34600.00021.557410.0000AID625243
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.86200.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.85500.00031.465610.0000AID625207
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)3.30800.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.94500.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)1.27200.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.66600.00010.954910.0000AID625218
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.63800.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.33900.00000.70488.1930AID625222
C-8 sterol isomeraseSaccharomyces cerevisiae S288CKi0.16000.00000.90487.1500AID239296
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)1.31900.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.44800.00000.602010.0000AID625254
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)1.36300.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.86700.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)5.35000.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki3.02400.00000.965010.0000AID625196
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)1.52200.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.70700.00020.522910.0000AID625221
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)0.78400.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.62300.00021.11158.0280AID625256
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)Ki0.00100.00040.54906.7000AID239597
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.02900.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.01000.00000.490110.0000AID239347; AID625223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
protein AF-9 isoform aHomo sapiens (human)AC500.52900.08008.380217.9800AID720495
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (528)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
cholesterol biosynthetic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol metabolic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
hemopoiesis3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via desmosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via lathosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
ossification involved in bone maturation3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (148)

Processvia Protein(s)Taxonomy
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
C-8 sterol isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
steroid delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
identical protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholestenol delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (94)

Processvia Protein(s)Taxonomy
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
nuclear envelope3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cytoplasmic vesicle3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID239296Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1815134Synergistic antibacterial activity against community acquired methicillin resistant Staphylococcus aureus USA300 assessed as potentiation of cefuroxime-induced antibacterial activity by measuring cefuroxime fractional inhibitory concentration incubated fo2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Structural Insights into the Inhibition of Undecaprenyl Pyrophosphate Synthase from Gram-Positive Bacteria.
AID239597Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID1661954Binding affinity to Ebola virus glycoprotein assessed as dissociation constant incubated for 20 to 30 mins by microscale thermophoresis2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
AID1557361Binding affinity to HIV1 RRE RNA assessed as reduction in binding of tritiated RRE RNA to biotinylated Rev protein by high-throughput scintillation proximity assay2019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1815133Synergistic antibacterial activity against community acquired methicillin resistant Staphylococcus aureus USA300 assessed as potentiation of cefuroxime-induced antibacterial activity by measuring cefuroxime MIC incubated for 18 hrs by checkerboard broth m2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Structural Insights into the Inhibition of Undecaprenyl Pyrophosphate Synthase from Gram-Positive Bacteria.
AID1557362Antiviral activity against HIV1 assessed as reduction in viral replication by cell based assay2019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1815131Synergistic antibacterial activity against community acquired methicillin resistant Staphylococcus aureus USA300 incubated for 18 hrs by checkerboard broth microdilution assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Structural Insights into the Inhibition of Undecaprenyl Pyrophosphate Synthase from Gram-Positive Bacteria.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID55146Inhibitory concentration against ethidium bromide binding to DNA1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer.
AID1815132Synergistic antibacterial activity against community acquired methicillin resistant Staphylococcus aureus USA300 assessed as fractional inhibitory concentration incubated for 18 hrs by checkerboard broth microdilution assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Structural Insights into the Inhibition of Undecaprenyl Pyrophosphate Synthase from Gram-Positive Bacteria.
AID1815135Synergistic antibacterial activity against community acquired methicillin resistant Staphylococcus aureus USA300 assessed as fractional inhibitory concentration index in presence of cefuroxime incubated for 18 hrs by checkerboard broth microdilution assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Structural Insights into the Inhibition of Undecaprenyl Pyrophosphate Synthase from Gram-Positive Bacteria.
AID239347Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID213588The compound was tested for relative binding affinity against calf uterine receptor using [3H]estradiol as radioligand1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,060)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902711 (53.58)18.7374
1990's803 (15.87)18.2507
2000's669 (13.22)29.6817
2010's685 (13.54)24.3611
2020's192 (3.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.03 (24.57)
Research Supply Index8.72 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index168.74 (26.88)
Search Engine Supply Index3.76 (0.95)

This Compound (51.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials677 (12.39%)5.53%
Reviews622 (11.38%)6.00%
Case Studies384 (7.03%)4.05%
Observational11 (0.20%)0.25%
Other3,772 (69.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (137)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome [NCT01157312]113 participants (Actual)Interventional2008-08-31Completed
Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene [NCT01289756]Phase 120 participants (Actual)Interventional2009-12-31Completed
Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy on Improvement of Endometrial Thickness and Treatment of Unexplained Infertility [NCT05753098]Phase 4148 participants (Actual)Interventional2021-01-15Completed
Evaluate the Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination [NCT01219101]Phase 495 participants (Actual)Interventional2011-03-31Completed
Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial [NCT02523898]Phase 2388 participants (Anticipated)Interventional2015-11-30Enrolling by invitation
"Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility:A Clinical Research of Same Treatment for Different Diseases" [NCT03709849]Phase 2528 participants (Anticipated)Interventional2019-02-01Not yet recruiting
Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome [NCT02344888]Phase 4300 participants (Anticipated)Interventional2015-02-28Recruiting
A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects [NCT02117830]Phase 154 participants (Anticipated)Interventional2014-04-30Completed
FSH and LH Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women [NCT01340521]Phase 1/Phase 225 participants (Actual)Interventional1991-03-31Completed
PHASE 2b RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY OF ANDROXAL IN IDIOPATHIC MALE INFERTILITY (PROTOCOL #01-14-40-08) [NCT02160704]Phase 2/Phase 30 participants (Actual)Interventional2014-09-22Withdrawn(stopped due to Difficult eligibility and lack of funding)
Intrauterine Infusion of Autologous Platelet-rich Plasma to Prevent a Thin Endometrium in Infertile Women Undergoing Clomiphene Citrate Therapy: a Pilot Prospective Self-controlled Trial [NCT03770026]Phase 2/Phase 330 participants (Actual)Interventional2018-01-01Completed
Among Non-IVF Patients Undergoing Ovulation Induction With Clomiphene Citrate (Clomid® 50 mg), Does Administration of an Increased Dose of Clomiphene Citrate (Clomid® 100 mg) Compared With Gonadotropins, Achieve Similar Rates of Folliculogenesis? [NCT00835744]Phase 440 participants (Actual)Interventional2008-08-31Completed
Clomiphene Citrate Versus Tamoxifen for Induction of Ovulation in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial [NCT02479256]Phase 4600 participants (Actual)Interventional2015-06-30Completed
Trigger or Not to Trigger? : An Answer for an Old Question [NCT02264847]Phase 3200 participants (Anticipated)Interventional2014-10-31Recruiting
Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole [NCT03241472]Phase 3100 participants (Actual)Interventional2016-02-29Completed
Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility [NCT03681197]Early Phase 1170 participants (Anticipated)Interventional2018-06-15Recruiting
Evaluation of the Clinical Outcome of Vitamin E as Adjuvant Therapy in Patients With Clomiphene Citrate Resistant Polycystic Ovary Syndrome [NCT03674385]Phase 260 participants (Actual)Interventional2018-07-19Completed
Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome [NCT03630341]Phase 4150 participants (Actual)Interventional2016-02-01Completed
Effects of Vitamin D Supplementation on Reproductive, Hormonal and Metabolic Profiles, and on IVF Outcomes, in PCOS Infertile Saudi Women : a Randomized-controlled Clinical Trial [NCT05106712]700 participants (Anticipated)Interventional2021-11-01Not yet recruiting
An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal [NCT02169804]Phase 124 participants (Actual)Interventional2014-08-31Completed
Effect of Adding Vitamin D Supplement to Clomiphene Citrate for Induction of Ovulation in Overweight Women With Polycystic Ovary Syndrome [NCT03396380]Phase 3186 participants (Anticipated)Interventional2017-07-01Recruiting
Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility: Randomized Controlled Trial [NCT03549741]Phase 2/Phase 3120 participants (Anticipated)Interventional2018-07-31Not yet recruiting
Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome [NCT02255578]Phase 350 participants (Anticipated)Interventional2014-09-30Not yet recruiting
Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial [NCT02186782]Phase 4600 participants (Anticipated)Interventional2014-06-30Recruiting
Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF: a Randomized Study [NCT02201914]Phase 4250 participants (Anticipated)Interventional2014-01-31Recruiting
The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial [NCT01213147]Phase 4159 participants (Actual)Interventional2009-04-30Completed
L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome [NCT03476356]106 participants (Actual)Interventional2017-11-01Completed
Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Non Polycystic Ovarian Syndrome Patients [NCT02330757]Phase 4150 participants (Anticipated)Interventional2016-10-10Recruiting
Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination [NCT01232075]Phase 2214 participants (Actual)Interventional2008-09-30Completed
Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer [NCT03309436]Phase 4360 participants (Anticipated)Interventional2017-08-07Recruiting
Combined Coenzyme Q10 and Clomiphene Citrate for Ovulation Induction in Clomiphene-citrate-resistant Polycystic Ovary Syndrome [NCT04302532]Phase 4149 participants (Actual)Interventional2020-07-01Completed
Effect of Sildenafil Citrate on Pregnancy Rate in Women Undergoing Induction of Ovulation [NCT02890238]Phase 4100 participants (Anticipated)Interventional2016-08-31Recruiting
Comparison of Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF: a Prospective Cohort Study [NCT02690870]Phase 4210 participants (Anticipated)Interventional2017-01-31Not yet recruiting
AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL [NCT02146391]Phase 112 participants (Actual)Interventional2014-06-30Completed
Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects. [NCT02380755]Phase 278 participants (Actual)Interventional2015-04-30Completed
Prospective Randomized Trial on the Effect of Clomiphene Citrate Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and Pregnancy Outcome. [NCT02237755]Phase 2/Phase 350 participants (Anticipated)Interventional2014-10-31Not yet recruiting
Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome [NCT02802865]Phase 470 participants (Actual)Interventional2016-08-31Completed
Combined Pioglitazone and Clomophene Citrate Versus Combined Metformin and Clomiphene Citrate as First Treatment in Infertile Women With Polycystic Ovary Syndrome [NCT03566225]Early Phase 1400 participants (Actual)Interventional2018-01-30Completed
Effect of Ubiquinol Supplementation on Ovulation Induction in Clomiphene Citrate Resistance [NCT04870502]Phase 2/Phase 3161 participants (Actual)Interventional2019-04-01Completed
Use of Low Dose of Human Chorionic Gonadotropin During Ovulation Induction With Clomiphene Citrate in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome [NCT02436226]Phase 4300 participants (Actual)Interventional2016-03-31Completed
Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome [NCT02551367]Phase 2110 participants (Anticipated)Interventional2015-10-31Not yet recruiting
Pharmacokinetics and Hepatic Safety of EGCG [NCT04177693]Phase 139 participants (Actual)Interventional2020-11-24Completed
Myo-inositol Versus Clomiphene Citrate as First Line Treatment for Ovulation Induction in PCOS [NCT04306692]Phase 412 participants (Actual)Interventional2020-07-02Terminated(stopped due to clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome)
N-acetyl-cysteine in Clomiphene Citrate Resistant Polycystic Ovary Syndrome After Laparoscopic Ovarian Drilling: A Randomized Controlled Trial [NCT02775734]Phase 2/Phase 3144 participants (Actual)Interventional2016-05-31Completed
Clomiphene Citrate Plus Cabergoline Versus Clomiphene Citrate Alone in Treatment of Polycystic Ovary Syndrome Associated Infertility [NCT02644304]Phase 288 participants (Anticipated)Interventional2015-05-31Recruiting
A Comparison of Hormonal Profile and the Follicular Development Between Letrozole and Clomifene Citrate in Anovulatory Women With Polycystic Ovary Syndrome and Ovulatory Women [NCT02647424]40 participants (Anticipated)Interventional2015-12-31Recruiting
Oral Sildenafil Citrate: a Potential Approach for Improvement of Endometrial Thickness and Treatment of Unexplained Infertility in Women [NCT05846906]Phase 2/Phase 3130 participants (Actual)Interventional2021-10-01Completed
Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism [NCT00697814]Phase 215 participants (Actual)Interventional2004-06-30Completed
Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome [NCT00795808]Phase 4171 participants (Actual)Interventional2003-08-31Completed
The Effect of Incremental Clomiphene Citrate(CC) Doses in Successive Induction Cycles on the Endogenous Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Steroid Hormone Responses to Treatment [NCT04210765]Phase 450 participants (Actual)Interventional2019-08-02Completed
Protocol to Minimize Injections and Blood Draws for Women Undergoing Controlled Ovarian Hyperstimulation for in Vitro Fertilization [NCT02865681]4 participants (Actual)Interventional2016-07-01Completed
An Open, Randomized, Parallel-Group, Multicentric, Comparative Study of Letrozole With Clomiphene Citrate for Induction of Ovulation in Anovulatory Infertility. [NCT00610077]Phase 355 participants (Actual)Interventional2004-12-31Completed
A One Year Open Label Study of Androxal in the Treatment of Secondary Hypogonadism in Men Who Have Completed Protocol ZA-203 [NCT01386567]Phase 248 participants (Actual)Interventional2011-07-31Completed
Evaluation of the Effect of Pentoxifylline and α-Lipoic Acid as Adjunctive Therapy in Patients With Clomiphene Citrate Resistant Polycystic Ovary Syndrome [NCT05231980]Phase 2120 participants (Actual)Interventional2022-06-05Completed
Mild Stimulation Protocol Using Clomiphene Citrate / Gonadotropins Versus Conventional Stimulation Protocol for Women With PCOS Undergoing in Vitro Fertilization (IVF): a Prospective Non-randomized Controlled Trial [NCT04157725]Phase 4154 participants (Anticipated)Interventional2023-06-01Active, not recruiting
Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients [NCT02544776]60 participants (Actual)Interventional2015-01-31Completed
Different Variables Predicting Ovulatory Response Among Clomiphene Citrate Resistance and Clomiphene Citrate Sensitive Patients With Polycystic Ovarian Syndrome. [NCT04887402]100 participants (Anticipated)Observational [Patient Registry]2021-01-01Recruiting
Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study [NCT01004068]Phase 496 participants (Actual)Interventional2008-02-29Completed
An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003 [NCT01067365]Phase 3104 participants (Actual)Interventional2006-03-31Completed
A Comparison of Clomiphene Citrate Responses in Men With Hypothalamic Hypogonadism naïve to, and Previously Treated With, Testosterone [NCT01904734]Phase 242 participants (Actual)Interventional2012-10-31Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Open-Label, Active-Controlled Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism [NCT00962637]Phase 3194 participants (Actual)Interventional2006-03-31Completed
[NCT00844350]Phase 2177 participants (Actual)Interventional2006-10-31Completed
Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome [NCT00427700]Phase 382 participants (Actual)Interventional2008-08-31Completed
Combined Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in CC-resistant Patients With Polycystic Ovary Syndrome [NCT01910766]110 participants (Actual)Interventional2010-01-31Completed
Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate [NCT05096169]Phase 240 participants (Anticipated)Interventional2022-05-01Recruiting
AN OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE DRUG-DRUG INTERACTIONS OF ANDROXAL WITH CYTOCHROME P450 ISOENZYMES IN HEALTHY MALE SUBJECTS [NCT01991327]Phase 130 participants (Actual)Interventional2014-05-31Completed
[NCT01993212]Phase 3120 participants (Actual)Interventional2014-01-31Completed
[NCT01993225]Phase 3120 participants (Actual)Interventional2014-01-31Completed
Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial [NCT02024984]Phase 190 participants (Anticipated)Interventional2013-11-30Recruiting
Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest [NCT02575248]Phase 4310 participants (Anticipated)Interventional2014-10-31Recruiting
Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome. [NCT00830492]Phase 4200 participants (Anticipated)Interventional2008-01-31Completed
The Added Value of n Acetyle Cysteine and Chromium to Clomiphene Citrate in PCO [NCT04170439]108 participants (Actual)Interventional2019-11-20Completed
The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene: A Randomized Controlled Trial. [NCT02663830]Phase 2210 participants (Actual)Interventional2016-01-10Completed
Patients With Reduced Ovarian Reserve and In Vitro Fertilization (IVF) Cycles. A Randomized Multicentric Comparison of a Protocol With High Doses of Gonadotropins and a Protocol With Clomiphene Citrate Only. Evaluation of Clinical Effectiveness and Econom [NCT01389713]289 participants (Actual)Interventional2008-09-30Completed
Cost-effective Treatment of Unexplained Infertility: A Prospective Multicenter, Double-blinded, Randomised Controlled Study [NCT06178523]Phase 4900 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome [NCT00471523]Phase 480 participants (Actual)Interventional2006-05-31Completed
Comparison of Recombinant Follicle Stimulating Hormone and the Combination of Recombinant Follicle Stimulating Hormone With Clomiphene Citrate in Stimulated Intrauterine Insemination Cycles: A Prospective Randomized Controlled Multicentric Study [NCT05670795]254 participants (Anticipated)Interventional2023-01-01Recruiting
Optimizing Fertility Treatment in Women With Polycystic Ovary Syndrome (PCOS) - A Randomized Controlled Trial: The Role of Progestin-induced Endometrial Shedding in PCOS (PIES in PCOS) [NCT01718444]27 participants (Actual)Interventional2015-03-31Terminated(stopped due to The primary investigator moved from academic practice to join a private group, and could not get any one to take over as PI for the study.)
Prospective Randomized Study of Ovulation Induction Using Either Tamoxifen or Clomiphene Citrate for Women Who Had Thin Endometrium During Previous Treatment With Clomiphene Citrate [NCT00449514]100 participants (Anticipated)Interventional2007-05-31Recruiting
How Long Should First-line Treatment be Continued in Infertile PCOS Patients Who Ovulate Under Clomiphene Citrate? A Randomized Controlled Clinical Study. [NCT00501839]Phase 40 participants (Actual)Interventional2008-08-31Withdrawn
What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study. [NCT00502229]Phase 40 participants (Actual)Interventional2010-01-31Withdrawn
Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial [NCT00558077]Phase 450 participants (Actual)Interventional2003-02-28Completed
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome: Randomised Control Trial [NCT05702957]Phase 2/Phase 3220 participants (Actual)Interventional2016-09-30Completed
A Randomized Double Blinded Placebo Controlled Trial Between Anastrozole and Clomiphene to Evaluate Improvement in Hypogonadal Symptoms and Erectile Function Using ADAM, IIEF and EHS Validated Scales [NCT03933618]Phase 224 participants (Actual)Interventional2015-04-02Completed
Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome [NCT00068861]Phase 3678 participants Interventional2002-11-30Completed
An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism [NCT01739582]Phase 3300 participants (Anticipated)Interventional2012-11-30Completed
Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Polycystic Ovarian Syndrome Patients [NCT02273791]126 participants (Actual)Observational2013-12-31Completed
Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome [NCT00478504]Phase 4159 participants (Actual)Interventional2007-05-31Completed
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration [NCT02274181]Phase 16 participants (Actual)Interventional2014-12-31Completed
Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial [NCT00461643]Phase 4552 participants (Anticipated)Interventional2007-01-31Recruiting
Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia [NCT01529177]Phase 4600 participants (Anticipated)Interventional2012-02-29Recruiting
The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial [NCT00413179]Phase 356 participants Interventional1997-12-31Completed
Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in Agonist Triggered GnRH Antagonist in Vitro Fertilization Cycles. Phase IV, Single-centre, Open-label, Controlled Clinical Trial. [NCT01791751]Phase 410 participants (Actual)Interventional2012-06-30Completed
Comparative Study of Pregnancy Rate After Endometrial Injury in Couples With Unexplained Infertility [NCT03398993]100 participants (Anticipated)Interventional2018-01-31Not yet recruiting
An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism [NCT01534208]Phase 3499 participants (Actual)Interventional2012-05-31Completed
A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism [NCT01270841]Phase 283 participants (Actual)Interventional2011-01-31Completed
A Double-Blind Crossover Study In Healthy Volunteers to Compare Two Formulations of Androxal [NCT01984398]Phase 116 participants (Actual)Interventional2013-12-31Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Administered Intravenously or Subcutaneously (Via Portable Infusion Pump) Compared to Oral Treatment With Clomi [NCT00296465]Phase 2/Phase 3132 participants (Actual)Interventional2005-02-28Completed
A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism [NCT01619683]Phase 3300 participants (Actual)Interventional2012-09-30Completed
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome (PCOS) and a Resistance to Insulin. Randomised Controlled Study [NCT01638988]Phase 30 participants (Actual)Interventional2013-09-30Withdrawn(stopped due to Previous studies have been done regarding same condition)
[NCT01784380]1,159 participants (Actual)Observational2006-10-31Completed
Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women [NCT01793038]160 participants (Anticipated)Interventional2013-03-31Recruiting
A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment [NCT01191320]Phase 2102 participants (Actual)Interventional2010-10-31Completed
Traditional Clomiphene Citrate Administration Versus a Stair-Step Approach: A Randomized Controlled Trial [NCT01008319]Phase 3120 participants (Actual)Interventional2009-10-31Completed
Phytoestrogens as an Alternative to Estradiol in Reversing the Antiestrogenic Effect of Clomid on Endometrium in Ovulation Induction in Cases of Polycystic Ovarian Syndrome [NCT02352597]Phase 4150 participants (Actual)Interventional2013-01-31Completed
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment With Clomiphene Citr [NCT00796289]Phase 2350 participants (Actual)Interventional2009-02-28Completed
[NCT00005104]99 participants Interventional2000-01-31Completed
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function [NCT01923857]Phase 126 participants (Actual)Interventional2013-08-31Completed
Clomiphene Citrate Stair-step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome: A Randomized Clinical Trial [NCT03178500]60 participants (Anticipated)Interventional2017-02-01Recruiting
Randomized Prospective Controlled Non-inferiority Trial of Low-dose Clomiphene Based Antagonist Protocol vs. High Dose Gonadotropin/Antagonist Protocol for IVF Poor Responders [NCT01577199]Phase 40 participants (Actual)Interventional2012-04-30Withdrawn(stopped due to no subjects recruited)
An Open Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Hepatic Function [NCT01923870]Phase 119 participants (Actual)Interventional2013-08-31Completed
Effect of High BMI on Ovulation Induction Using Letrozole Versus Clomid [NCT04331197]Phase 4160 participants (Anticipated)Interventional2020-05-01Not yet recruiting
[NCT00005654]88 participants Interventional2000-01-31Completed
Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome [NCT01909141]Early Phase 1100 participants (Actual)Interventional2013-08-31Completed
A Dose Escalating Study To Determine the Tolerability and Pharmacokinetics of a Single Dose of Androxal in Healthy Volunteers [NCT01959685]Phase 19 participants (Actual)Interventional2013-10-31Completed
Effect of Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate on Endometrial Thickness in Infertile Women With Prior Clomiphene Citrate Failure Due to Thin Endometrium: a Prospective Self-controlled Clinical Trial [NCT02710981]42 participants (Actual)Interventional2015-06-30Completed
Interest of Clomiphene Citrate (CC) Associated With a Second Testicular Sperm Extraction (TESE) in Patients With Non-obstructive Azoospermia (NOA) After Failure of a First TESE, on the Quantity of Sperm Cells Available for Intracytoplasmic Sperm Injection [NCT03615547]Phase 3128 participants (Anticipated)Interventional2023-01-31Not yet recruiting
Extended Clomiphene Citrate Regimen Versus Laparoscopic Ovarian Drilling for Ovulation Induction in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome [NCT02381184]Phase 2/Phase 3160 participants (Actual)Interventional2014-06-30Completed
Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome [NCT03316469]40 participants (Anticipated)Interventional2018-07-31Not yet recruiting
Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles [NCT02345837]160 participants (Anticipated)Interventional2014-02-28Recruiting
A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men [NCT01386606]Phase 260 participants (Actual)Interventional2011-06-30Completed
A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration [NCT01532414]Phase 3151 participants (Actual)Interventional2012-08-31Completed
A Randomized, Open-Label, Fixed Dose, Active-Control, Multi-Center Phase IIB Study to Evaluate Fertility in Men With Secondary Hypogonadism, Comparing Androxal® to a Topical Testosterone in Men Previously Treated With Topical Testosterone. [NCT00706719]Phase 217 participants (Actual)Interventional2008-06-30Completed
Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial [NCT05089344]132 participants (Anticipated)Interventional2021-10-09Recruiting
Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting [NCT03028532]Phase 112 participants (Actual)Interventional2017-03-13Completed
A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration [NCT01739595]Phase 3181 participants (Actual)Interventional2012-11-30Completed
A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile [NCT00213148]Phase 2271 participants (Actual)Interventional2005-03-10Completed
Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial [NCT04944836]Phase 258 participants (Anticipated)Interventional2023-03-09Recruiting
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation [NCT01044862]Phase 3900 participants (Actual)Interventional2010-06-30Completed
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation [NCT05206448]Phase 4189 participants (Actual)Interventional2020-10-26Active, not recruiting
A 20 Week Double-Blind Randomized Trial of Clomiphene Citrate and Letrozole for the Treatment of Infertility in Women With Polycystic Ovary Syndrome [NCT00719186]Phase 3750 participants (Actual)Interventional2009-02-28Completed
The Effect Of Vitamin D Replacement Therapy On Serum Leptin And Follicular Growth Pattern In Women With Resistant Polycystic Ovarian Syndrome [NCT03806036]Phase 4100 participants (Anticipated)Interventional2018-01-02Recruiting
Determining the Fertility Benefit of Immediate SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis [NCT02520505]0 participants (Actual)Interventional2015-04-30Withdrawn(stopped due to no participants enrolled)
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome During Induction of Ovulation With Clomiphene Citrate [NCT03059173]Phase 3276 participants (Anticipated)Interventional2022-03-31Not yet recruiting
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 m [NCT02651688]Phase 250 participants (Actual)Interventional2016-01-11Completed
Clomiphene Citrate for the Treatment of Opioid-Induced Androgen Deficiency: Randomized Controlled Clinical Trial [NCT01880086]Phase 213 participants (Actual)Interventional2013-08-31Completed
Clomiphene Citrate for Treatment of Acromegaly Not Controlled by Conventional Therapies [NCT02274311]Phase 216 participants (Actual)Interventional2011-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00213148 (2) [back to overview]Ovulation Rate in Cycle 1
NCT00213148 (2) [back to overview]Number of Subjects With Clinical Pregnancy in Cycle 1
NCT00427700 (2) [back to overview]Percentage of Participants With Ovulation Detected by Ultrasound
NCT00427700 (2) [back to overview]Serum Levels of Progesterone
NCT00706719 (5) [back to overview]Luteinizing Hormone (LH) Levels
NCT00706719 (5) [back to overview]Sperm Concentration
NCT00706719 (5) [back to overview]Follicle Stimulating Hormone (FSH) Levels
NCT00706719 (5) [back to overview]Motile Total Sperm Count
NCT00706719 (5) [back to overview]Semen Volume
NCT00719186 (5) [back to overview]Number of Serious Adverse Events
NCT00719186 (5) [back to overview]Number of Pregnancy
NCT00719186 (5) [back to overview]Number of Ovulations
NCT00719186 (5) [back to overview]Live Birth
NCT00719186 (5) [back to overview]Neonatal Complication Rate
NCT01008319 (2) [back to overview]Delivery Outcomes
NCT01008319 (2) [back to overview]Time to Ovulation With Each Protocol
NCT01044862 (4) [back to overview]Time to Pregnancy
NCT01044862 (4) [back to overview]Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.
NCT01044862 (4) [back to overview]Live Birth Rate
NCT01044862 (4) [back to overview]Rate of Pregnancy Obtained
NCT01191320 (1) [back to overview]Change in HbA1C
NCT01270841 (4) [back to overview]Reproductive Safety
NCT01270841 (4) [back to overview]Change in Total Morning Testosterone
NCT01270841 (4) [back to overview]Change in Luteinizing Hormone Levels
NCT01270841 (4) [back to overview]Change in FSH After 3 Months of Treatment
NCT01386606 (7) [back to overview]Enclomiphene Pharmacokinetic Parameters at Week 6 - Tmax.
NCT01386606 (7) [back to overview]Morning Testosterone Correlated With Serial Testosterone.
NCT01386606 (7) [back to overview]24 Hour Average and Maximum Testosterone Concentration
NCT01386606 (7) [back to overview]Change in Follicle Stimulating Hormone (FSH)
NCT01386606 (7) [back to overview]Change in Leuteinizing Hormone (LH)
NCT01386606 (7) [back to overview]Enclomiphene Pharmacokinetic Parameters at Week 6 - AUC0-24.
NCT01386606 (7) [back to overview]Enclomiphene Pharmacokinetic Parameters at Week 6 - Cmax.
NCT01532414 (2) [back to overview]Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range
NCT01532414 (2) [back to overview]Subjects With 50% or Greater Decrease in Sperm Concentration Comparison of Proportion of Subjects With 50% or Greater Decrease in Sperm
NCT01534208 (6) [back to overview]Absolute Values of Morning Testosterone
NCT01534208 (6) [back to overview]Change From Baseline in BMI
NCT01534208 (6) [back to overview]Change From Baseline in FSH
NCT01534208 (6) [back to overview]Change From Baseline in LH
NCT01534208 (6) [back to overview]Change From Baseline in Total Morning Testosterone at 26 Weeks
NCT01534208 (6) [back to overview]Mean Change From Baseline FPG
NCT01739595 (2) [back to overview]Subjects With Testosterone in Normal Range After Treatment
NCT01739595 (2) [back to overview]Change in Sperm Concentration
NCT01880086 (7) [back to overview]Androgen Deficiency in the Aging Male (ADAM) Questionnaire
NCT01880086 (7) [back to overview]Estradiol
NCT01880086 (7) [back to overview]Hematocrit (%)
NCT01880086 (7) [back to overview]Men's Sexual Health Questionnaire (MSHQ) Questionnaire
NCT01880086 (7) [back to overview]Other Hormonal Profile (Change From Baseline)
NCT01880086 (7) [back to overview]Serum Total Testosterone (Change From Baseline)
NCT01880086 (7) [back to overview]Sexual Health Inventory for Men (SHIM) Questionnaire
NCT01909141 (5) [back to overview]Ovulation Rate
NCT01909141 (5) [back to overview]Pregnancy Rate
NCT01909141 (5) [back to overview]Safety of Pioglitazone as Regards Serum Creatinine
NCT01909141 (5) [back to overview]Number of Follicles>18mm.
NCT01909141 (5) [back to overview]Endometrial Thickness
NCT01959685 (2) [back to overview]Cmax of a Single Dose of 250 mg Androxal
NCT01959685 (2) [back to overview]Pharmacokinetics
NCT01984398 (2) [back to overview]Androxal Cmax Formulation B
NCT01984398 (2) [back to overview]Androxal Cmax Formulation A
NCT02274311 (3) [back to overview]Testosterone Levels
NCT02274311 (3) [back to overview]IGF-1 Levels
NCT02274311 (3) [back to overview]PSA Levels
NCT02651688 (20) [back to overview]Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Estradiol (E2) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Glucose Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Testosterone (T) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Body Mass Index (BMI) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Body Strength (Chest Press Weight) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Body Strength (Leg Press Weight) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Lean Body Mass (LBM) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Waist Circumference at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Weight at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Leptin Level at Week 48
NCT02710981 (3) [back to overview]Endometrial Thickness
NCT02710981 (3) [back to overview]Uterine Blood Flow
NCT02710981 (3) [back to overview]Clinical Pregnancy Rate
NCT02802865 (9) [back to overview]Clinical Pregnancy
NCT02802865 (9) [back to overview]Size of Largest Developing Follicle
NCT02802865 (9) [back to overview]Pregnancy Loss
NCT02802865 (9) [back to overview]Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level
NCT02802865 (9) [back to overview]Number of Developing Follicles
NCT02802865 (9) [back to overview]Multiple Gestation
NCT02802865 (9) [back to overview]Live Birth
NCT02802865 (9) [back to overview]Endometrial Thickness
NCT02802865 (9) [back to overview]Conception
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 24
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 24
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 8
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 16
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 16
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 16
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SHBG - Screen
NCT03933618 (95) [back to overview]SHBG - Screen
NCT03933618 (95) [back to overview]SHBG - Week 16
NCT03933618 (95) [back to overview]SHBG - Week 16
NCT03933618 (95) [back to overview]SHBG - Week 24
NCT03933618 (95) [back to overview]SHBG - Week 24
NCT03933618 (95) [back to overview]SHBG - Week 24
NCT03933618 (95) [back to overview]SHBG - Week 8
NCT03933618 (95) [back to overview]SHBG - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 16
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Screen
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 16
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 24
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 24
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 24
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 8
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 8
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Screen
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 16
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 16
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 24
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 24
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 24
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 8
NCT03933618 (95) [back to overview]Estradiol - Screen
NCT03933618 (95) [back to overview]Estradiol - Screen
NCT03933618 (95) [back to overview]Estradiol - Week 16
NCT03933618 (95) [back to overview]Estradiol - Week 16
NCT03933618 (95) [back to overview]Estradiol - Week 16
NCT03933618 (95) [back to overview]Estradiol - Week 24
NCT03933618 (95) [back to overview]Estradiol - Week 24
NCT03933618 (95) [back to overview]Estradiol - Week 24
NCT03933618 (95) [back to overview]Estradiol - Week 8
NCT03933618 (95) [back to overview]Estradiol - Week 8
NCT03933618 (95) [back to overview]Estradiol - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Screen
NCT03933618 (95) [back to overview]Free Testosterone - Screen
NCT03933618 (95) [back to overview]Free Testosterone - Screen
NCT03933618 (95) [back to overview]Free Testosterone - Week 16
NCT03933618 (95) [back to overview]Free Testosterone - Week 16
NCT03933618 (95) [back to overview]Free Testosterone - Week 16
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]FSH - Screen
NCT03933618 (95) [back to overview]FSH - Screen
NCT03933618 (95) [back to overview]FSH - Week 16
NCT03933618 (95) [back to overview]FSH - Week 16
NCT03933618 (95) [back to overview]FSH - Week 24
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 24
NCT03933618 (95) [back to overview]FSH - Week 24
NCT03933618 (95) [back to overview]FSH - Week 24
NCT03933618 (95) [back to overview]FSH - Week 8
NCT03933618 (95) [back to overview]FSH - Week 8
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Screen
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 16
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 16
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 24
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 24
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 8
NCT03933618 (95) [back to overview]LH - Screen
NCT03933618 (95) [back to overview]LH - Screen
NCT03933618 (95) [back to overview]LH - Week 16
NCT03933618 (95) [back to overview]LH - Week 16
NCT03933618 (95) [back to overview]LH - Week 24
NCT03933618 (95) [back to overview]LH - Week 24
NCT03933618 (95) [back to overview]LH - Week 24
NCT03933618 (95) [back to overview]LH - Week 8
NCT03933618 (95) [back to overview]LH - Week 8
NCT03933618 (95) [back to overview]Normalized Testosterone - Screen
NCT03933618 (95) [back to overview]Normalized Testosterone - Screen
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 16
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 16
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 24
NCT04177693 (11) [back to overview]Changes in Endometrial Thickness
NCT04177693 (11) [back to overview]Changes in Total Bilirubin
NCT04177693 (11) [back to overview]Changes in ALT/SGPT
NCT04177693 (11) [back to overview]Changes in Alkaline Phosphatase
NCT04177693 (11) [back to overview]Change in Serum Folate Level Between MTHFR677-Wild Type (WT) Group and MTHFR677-Hetero Group
NCT04177693 (11) [back to overview]Change in Serum Folate Level Between MTHFR1298-Wild Type (WT) Group and MTHFR1298-Hetero Group
NCT04177693 (11) [back to overview]Change in Serum Folate Level Between DHFR-Wild Type (WT) Group and DHFR-Hetero or Homo Group.
NCT04177693 (11) [back to overview]Changes in Estrogen (E2)
NCT04177693 (11) [back to overview]Changes in Epigallocatechin Gallate (EGCG)
NCT04177693 (11) [back to overview]Changes in Epigallocatechin (EGC)
NCT04177693 (11) [back to overview]Changes in Epicatechin Gallate(ECG)

Ovulation Rate in Cycle 1

Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron [P4] level greater than or equal to [>=] 10 nanogram per milliliter [ng/mL] and/or pregnancy). (NCT00213148)
Timeframe: Up to 1 month

Interventionpercentage of subjects (Number)
Clomiphene Citrate 50 mg64.9
Anastrozole 1 mg30.4
Anastrozole 5 mg36.8
Anastrozole 10 mg35.9

[back to top]

Number of Subjects With Clinical Pregnancy in Cycle 1

Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity. (NCT00213148)
Timeframe: Up to 1 month

Interventionsubjects (Number)
Clomiphene Citrate 50 mg10
Anastrozole 1 mg4
Anastrozole 5 mg7
Anastrozole 10 mg0

[back to top]

Percentage of Participants With Ovulation Detected by Ultrasound

Ovulation detected by ultrasound was defined as the percentage of a participants with ovulation detected by ultrasound, defined as the dominant follicle and its subsequent collapse. If a dominant follicle was not observed by day 21 after menses, the ovulation induction was considered to be a failure. (NCT00427700)
Timeframe: cycle day 14-20

Interventionpercentage of participants (Number)
Clomiphene52.5
Raloxifene40.4

[back to top]

Serum Levels of Progesterone

The level of serum progesterone that indicated ovulation was considered to be 3 ng/mL or greater, on days 8 to 10 after ovulation. (NCT00427700)
Timeframe: 8-10 days after ovulation

Interventionng/mL (Mean)
Clomiphene26.1
Raloxiphene40

[back to top]

Luteinizing Hormone (LH) Levels

LH levels were measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
InterventionmIU/mL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim3.400.880.602.68
Group B Androxal no Wash Out2.925.706.122.47

[back to top]

Sperm Concentration

Total sperm concentration was measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
Interventionmillions sperm/mL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim0.543.0023.1421.03
Group B Androxal no Wash Out72.8182.6168.5164.0

[back to top]

Follicle Stimulating Hormone (FSH) Levels

FSH levels were measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
InterventionmIU/mL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim3.381.060.93.6
Group B Androxal no Wash Out1.584.535.482.38

[back to top]

Motile Total Sperm Count

Motile total sperm count was measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
Interventionmillions sperm (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim0.32.4240.438
Group B Androxal no Wash Out99.0214.7146.9100.3

[back to top]

Semen Volume

Semen volume was measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
InterventionmL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim2.342.881.903.34
Group B Androxal no Wash Out2.232.452.482.40

[back to top]

Number of Serious Adverse Events

(NCT00719186)
Timeframe: as few as 5 months, up to 16 months

Interventionevents (Number)
Arm A: Clomiphene Citrate13
Arm B: Letrozole22

[back to top]

Number of Pregnancy

(NCT00719186)
Timeframe: as few as 5 months, up to 16 months

InterventionParticipants (Count of Participants)
Arm A: Clomiphene Citrate103
Arm B: Letrozole154

[back to top]

Number of Ovulations

(NCT00719186)
Timeframe: as few as 5 months, up to 16 months

Interventionovulations (Number)
Arm A: Clomiphene Citrate331
Arm B: Letrozole388

[back to top]

Live Birth

The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring. (NCT00719186)
Timeframe: as few as 5 months, up to 16 months

InterventionParticipants (Count of Participants)
Arm A: Clomiphene Citrate72
Arm B: Letrozole103

[back to top]

Neonatal Complication Rate

(NCT00719186)
Timeframe: September 2008 - December 2011

,
Interventionparticipants (Number)
Neonatal jaundiceNeonatal respiratory distress syndromeNeonatal hospitalization >3 daysIntrauterine growth restrictionNeonatal infectinMinor birth defectOther complicationCongenital anomalyNeonatal death
Arm A: Clomiphene Citrate1724120412
Arm B: Letrozole2774521541

[back to top]

Delivery Outcomes

Proportion of participants that delivered a baby based on which protocol they were randomized to. (NCT01008319)
Timeframe: 5 years

InterventionParticipants (Count of Participants)
Traditional Protocol21
Stair-Step Protocol21

[back to top]

Time to Ovulation With Each Protocol

We hypothesized that time to ovulation would be shorter with stair-step protocol vs. traditional. (NCT01008319)
Timeframe: 5 years

Interventiondays (Mean)
Traditional Administration31.1
Stair-Step Administration21.5

[back to top]

Time to Pregnancy

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventiondays (Mean)
Aromatase Inhibitors (AI)67.2
Clomiphene Citrate (CC)67.4
Follicle Stimulating Hormone (FSH)62.3

[back to top]

Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventionnumber of multiples (Number)
Aromatase Inhibitors (AI)9
Clomiphene Citrate (CC)8
Follicle Stimulating Hormone (FSH)34

[back to top]

Live Birth Rate

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventionparticipants (Number)
Aromatase Inhibitors (AI)56
Clomiphene Citrate (CC)70
Follicle Stimulating Hormone (FSH)97

[back to top]

Rate of Pregnancy Obtained

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventionparticipants (Number)
Aromatase Inhibitors (AI)85
Clomiphene Citrate (CC)106
Follicle Stimulating Hormone (FSH)140

[back to top]

Change in HbA1C

The change in HbA1c from Baseline to 3 Months for each treatment arm (NCT01191320)
Timeframe: 3 months

InterventionRatio (Mean)
Placebo0
Androxal 12.5 mg0
Androxal 25 mg0

[back to top]

Reproductive Safety

Change from baseline in sperm concentration (NCT01270841)
Timeframe: 3 months

Interventionmillions/mL (Mean)
Placebo-19.1
Testim (Topical Testosterone)-29.5
Androxal 12.5 mg8.2
Androxal 25 mg-2.8

[back to top]

Change in Total Morning Testosterone

Changes in values from baseline in total morning testosterone levels at month 3 comparing Androxal 12.5 and 25 mg to placebo and Testim (NCT01270841)
Timeframe: 3 months

Interventionng/dL (Mean)
Placebo-16.9
Testim (Topical Testosterone)253.7
Androxal 12.5 mg258.5
Androxal 25 mg197.3

[back to top]

Change in Luteinizing Hormone Levels

Changes in values from baseline in LH at month 3 (NCT01270841)
Timeframe: 3 months

InterventionmIU/mL (Mean)
Placebo-0.1
Testim (Topical Testosterone)-2.4
Androxal 12.5 mg4.8
Androxal 25 mg6.9

[back to top]

Change in FSH After 3 Months of Treatment

(NCT01270841)
Timeframe: 3 months

InterventionmIU/mL (Mean)
Placebo-0.2
Testim (Topical Testosterone)-4.4
Androxal 12.5 mg5.1
Androxal 25 mg7.4

[back to top]

Enclomiphene Pharmacokinetic Parameters at Week 6 - Tmax.

The Tmax for plasma concentration. (NCT01386606)
Timeframe: Week 6

Interventionh (Mean)
Androxal 6.25 mg2.33
Androxal 12.5 mg2.42
Androxal 25 mg2.41

[back to top]

Morning Testosterone Correlated With Serial Testosterone.

"9 AM morning testosterone correlated with Week 6 serial testosterone Cavg, Cmin, and Cmax.~If a subject did not have a Week 6 serial testosterone Cavg, Cmin, or Cmax then they were not included for that particular correlation calculation." (NCT01386606)
Timeframe: Week 6

InterventionNumber of Subjects (Number)
Androxal Pooled Dose Levels35

[back to top]

24 Hour Average and Maximum Testosterone Concentration

"The primary efficacy endpoint will be 24-hour average (TTavg) and maximum (TTmax) testosterone concentration compared to baseline after 6 weeks of treatment.~Time points (in hours after dosing) at which testosterone concentration was measured are: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24." (NCT01386606)
Timeframe: Baseline and Week 6

,,,
Interventionng/dL (Mean)
TTavg at BaselineTTavg at Week 6TTmax at BaselineTTmax at Week 6
AndroGel322.4543.9562.3930.1
Androxal 12.5 mg373.6460.8513.7607.5
Androxal 25 mg298.3586.7425.9764.3
Androxal 6.25 mg262.3392.4358.5524.5

[back to top]

Change in Follicle Stimulating Hormone (FSH)

Changes in morning FSH after continuous dosing (NCT01386606)
Timeframe: Baseline, Week 2, Week 4, Week 6

,,,
InterventionmIU/mL (Mean)
Morning FSH at BaselineMorning FSH at Week 2Morning FSH Change from Baseline at Week 2Morning FSH at Week 4Morning FSH Change from Baseline at Week 4Morning FSH at Week 6Morning FSH Change from Baseline at Week 6
AndroGel6.383.80-2.583.72-2.663.35-3.03
Androxal 12.5 mg5.637.772.147.121.488.192.56
Androxal 25 mg6.3111.415.0912.346.0313.457.14
Androxal 6.25 mg4.616.181.606.451.665.691.42

[back to top]

Change in Leuteinizing Hormone (LH)

Changes in morning LH after continuous dosing (NCT01386606)
Timeframe: Baseline, Week 2, Week 4, Week 6

,,,
InterventionmIU/mL (Mean)
Morning LH at BaselineMorning LH at Week 2Morning LH Change from Baseline at Week 2Morning LH at Week 4Morning LH Change from Baseline at Week 4Morning LH at Week 6Morning LH Change from Baseline at Week 6
AndroGel3.572.00-1.571.88-1.692.2-1.41
Androxal 12.5 mg4.828.603.787.202.388.23.39
Androxal 25 mg4.989.644.6611.786.7914.59.51
Androxal 6.25 mg3.635.491.996.923.436.12.60

[back to top]

Enclomiphene Pharmacokinetic Parameters at Week 6 - AUC0-24.

The area under the curve for plasma concentration over time from zero to 24 hours (AUC0-24). (NCT01386606)
Timeframe: Week 6

Interventionng*h/mL (Mean)
Androxal 6.25 mg21.200
Androxal 12.5 mg34.012
Androxal 25 mg150.51

[back to top]

Enclomiphene Pharmacokinetic Parameters at Week 6 - Cmax.

The Cmax for plasma concentration. (NCT01386606)
Timeframe: Week 6

Interventionng/mL (Mean)
Androxal 6.25 mg1.8154
Androxal 12.5 mg3.3899
Androxal 25 mg16.2993

[back to top]

Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range

"Proportion of pooled Androxal subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment. Cavg will be calculated as the numerical average of 24-hour serial testosterone assessments at 0, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours after dosing.~If the lower limit of the 95% confidence interval for the Androxal treatment group at Week 12 is at least 67%, then the co-primary endpoint based on the Cavg for testosterone has been achieved.~FDA specified primary endpoint did not include comparison to placebo, thus the proportion of placebo subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment was not calculated." (NCT01532414)
Timeframe: 3 months

InterventionPercentage of Subjects (Number)
Androxal Treated Subjects Pooled78.8

[back to top]

Subjects With 50% or Greater Decrease in Sperm Concentration Comparison of Proportion of Subjects With 50% or Greater Decrease in Sperm

"Proportion of subjects with a 50% or greater decrease in sperm concentration from baseline after 12 weeks of treatment in Androxal treated subjects to placebo.~The difference between the proportions (placebo minus Androxal) and corresponding 95% confidence interval was determined and compared to the equivalence limit of -20%. If the lower limit of the 95% confidence interval was greater than -20%, then Androxal would be concluded to be non-inferior to placebo in causing a 50% reduction in sperm concentrations." (NCT01532414)
Timeframe: 3 months

Interventionpercentage of participants (Number)
Androxal Subjects Pooled14.2
Placebo2.6

[back to top]

Absolute Values of Morning Testosterone

Absolute values of morning testosterone at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

Interventionng/dL (Mean)
Androxal 12.5 mg511.6
Androxal 25 mg416.7

[back to top]

Change From Baseline in BMI

Mean change from baseline in BMI at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

Interventionkg/m2 (Mean)
Androxal 12.5 mg0.2
Androxal 25 mg0.3

[back to top]

Change From Baseline in FSH

Change from baseline in FSH at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

InterventionU/L (Mean)
Androxal 12.5 mg5.20
Androxal 25 mg5.42

[back to top]

Change From Baseline in LH

Mean change from baseline in LH at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

InterventionmIu/mL (Mean)
Androxal 12.5 mg4.81
Androxal 25 mg4.27

[back to top]

Change From Baseline in Total Morning Testosterone at 26 Weeks

Changes in values from baseline of total morning testosterone levels at Week 26 (NCT01534208)
Timeframe: 6 months

Interventionng/dL (Mean)
Androxal 12.5 mg280.9
Androxal 25 mg214.7

[back to top]

Mean Change From Baseline FPG

Mean changes in Fasting Plasma Glucose from baseline to end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

Interventionmg/dL (Mean)
Androxal 12.5 mg-5.4
Androxal 25 mg-5.0

[back to top]

Subjects With Testosterone in Normal Range After Treatment

"Proportion (percent) of subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment. Cavg was calculated as the numerical average of 24-hour serial testosterone assessments at 0, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours after dosing.~If the lower limit of the 95% confidence interval for the Androxal treatment group at Week 12 is at least 67%, then the coprimary endpoint based on the Cavg for testosterone would have been achieved.~FDA specified primary endpoint did not include comparison to placebo, thus the proportion of placebo subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment was not calculated." (NCT01739595)
Timeframe: 3 months

InterventionPercentage of Subjects (Number)
Androxal Subjects Pooled81.3

[back to top]

Change in Sperm Concentration

"Proportion of subjects with a 50% or greater decrease in sperm concentration from baseline after 12 weeks of treatment in Androxal treated subjects to placebo.~The difference between the proportions (placebo minus Androxal) and corresponding 95% confidence interval was determined and compared to the equivalence limit of -20%. If the lower limit of the 95% confidence interval was greater than -20%, then Androxal would be concluded to be non-inferior to placebo in causing a 50% reduction in sperm concentrations." (NCT01739595)
Timeframe: 3 months

Interventionpercentage of subjects (Number)
Androxal Subjects Pooled14.2
Placebo4.3

[back to top]

Androgen Deficiency in the Aging Male (ADAM) Questionnaire

Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 0 and maximum score is 10. 0 is most symptomatic, and 10 is least symptomatic. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionscores on a scale (Mean)
Clomiphene Citrate8.0
Placebo8.0

[back to top]

Estradiol

(NCT01880086)
Timeframe: 3 months post initial visit

Interventionpg/mL (Mean)
Clomiphene Citrate23
Placebo25.2

[back to top]

Hematocrit (%)

Measure hematocrit from baseline. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionpercentage (Mean)
Clomiphene Citrate35.2
Placebo42.3

[back to top]

Men's Sexual Health Questionnaire (MSHQ) Questionnaire

Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 1, maximum score is 20. Minimum score is considered most symptomatic, maximum score is considered least symptomatic. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionscores on a scale (Mean)
Clomiphene Citrate7.0
Placebo8.8

[back to top]

Other Hormonal Profile (Change From Baseline)

Luteinizing hormone (LH) (NCT01880086)
Timeframe: 3 months post initial visit

InterventionIU/mL (Mean)
Clomiphene Citrate3.3
Placebo2.2

[back to top]

Serum Total Testosterone (Change From Baseline)

Morning venipuncture of serum total testosterone. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionng/mL (Mean)
Clomiphene Citrate322.5
Placebo179.8

[back to top]

Sexual Health Inventory for Men (SHIM) Questionnaire

Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 1, maximum score is 25. The minimum value is most symptomatic and maximum value is least symptomatic. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionscores on a scale (Mean)
Clomiphene Citrate12.2
Placebo18.5

[back to top]

Ovulation Rate

(NCT01909141)
Timeframe: 3 months

Interventionpercentage of all cycles (Number)
Arm 1:Letrozole-pioglitazone -Metformin Group93
Arm 2: Clomiphene Citrate-pioglitazone-metformin108

[back to top]

Pregnancy Rate

(NCT01909141)
Timeframe: 3 months

Interventionparticipants (Number)
Arm 1:Letrozole-pioglitazone -Metformin Group28
Arm 2: Clomiphene Citrate-pioglitazone-metformin24

[back to top]

Safety of Pioglitazone as Regards Serum Creatinine

serum creatinine was measured at the end of the study period (after 3 months) in both groups. (NCT01909141)
Timeframe: 3 months

Interventionmg/dL (Mean)
Arm 1:Letrozole-pioglitazone -Metformin Group0.62
Arm 2: Clomiphene Citrate-pioglitazone-metformin0.57

[back to top]

Number of Follicles>18mm.

(NCT01909141)
Timeframe: 3 months

Interventionfollicles (Mean)
Arm 1:Letrozole-pioglitazone -Metformin Group1.44
Arm 2: Clomiphene Citrate-pioglitazone-metformin1.5

[back to top]

Endometrial Thickness

(NCT01909141)
Timeframe: 3 months

Interventionmm (Mean)
Arm 1:Letrozole-pioglitazone -Metformin Group10.56
Arm 2: Clomiphene Citrate-pioglitazone-metformin9.68

[back to top]

Cmax of a Single Dose of 250 mg Androxal

(NCT01959685)
Timeframe: 24 hours

Interventionng/dL (Mean)
Up to 250 mg Androxal24.9

[back to top]

Pharmacokinetics

Cmax of a single dose 125 mg of Androxal (NCT01959685)
Timeframe: 24 hrs

Interventionng/dL (Mean)
Up to 250 mg Androxal11.0

[back to top]

Androxal Cmax Formulation B

To determine and compare the PK parameter Cmax between two formulations of Androxal (NCT01984398)
Timeframe: 24 hours

Interventionng/mL (Mean)
12.5 mg Androxal Formulation B1.08
25 mg Androxal Formulation B1.74

[back to top]

Androxal Cmax Formulation A

To determine and compare the pharmacokinetic parameter Cmax between two formulations of Androxal (NCT01984398)
Timeframe: 24 hours

Interventionng/mL (Mean)
12.5 mg Androxal Formulation A0.999
25 mg Androxal Formulation A1.67

[back to top]

Testosterone Levels

The objective is to compare the change of testosterone value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90). (NCT02274311)
Timeframe: D90

Interventionng/dL (Median)
Clomiphene Citrate282

[back to top]

IGF-1 Levels

The objective is to compare the change of IGF-1 value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90). (NCT02274311)
Timeframe: Day 90

Interventionng/mL (Mean)
Clomiphene Citrate424

[back to top]

PSA Levels

The objective is to compare the change of PSA value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90). (NCT02274311)
Timeframe: Day 90

Interventionng/mL (Median)
Clomiphene Citrate2.0

[back to top]

Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter CRP. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionmg/dL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg0.250.06
Enclomiphene 25 mg0.35-0.05
Placebo0.35-0.15

[back to top]

Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter DHT. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionnanogram per deciliter (ng/dL) (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg18.7815.13
Enclomiphene 25 mg16.0620.75
Placebo15.734.25

[back to top]

Change From Baseline in Blood Estradiol (E2) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter E2. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg50.04-3.00
Enclomiphene 25 mg48.4313.03
Placebo45.49-11.46

[back to top]

Change From Baseline in Blood Glucose Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter Glucose. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg98.39-1.81
Enclomiphene 25 mg101.41-5.25
Placebo97.93-4.33

[back to top]

Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter IL-6. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg2.230.56
Enclomiphene 25 mg3.38-0.21
Placebo2.75-0.78

[back to top]

Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter LH measured in milli-International Units per milliliter (mIU/mL). A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
InterventionmIU/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg3.932.40
Enclomiphene 25 mg3.413.01
Placebo3.510.83

[back to top]

Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48

Quantose-IR is a laboratory-developed test that assesses insulin resistance. Quantose-IR score is based on a linear regression algorithm utilizing the quantitative measures (natural log transformed) of alpha-hydroxybutyrate, oleate, linoleoylglycerophosphocholine and insulin and was designed to estimate the natural log of insulin-induced glucose infusion rate normalized by whole body mass. The algorithm score is converted to the Quantose-IR score within a range of 1-120 by an arithmetic calculation where higher scores denote greater insulin resistance. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
InterventionQuantose-IR score (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg75.74-3.96
Enclomiphene 25 mg76.50-6.59
Placebo78.05-6.50

[back to top]

Change From Baseline in Blood Testosterone (T) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter T. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionng/dL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg243.56173.81
Enclomiphene 25 mg218.24237.17
Placebo223.5343.33

[back to top]

Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter TNF-α . A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg1.77-0.63
Enclomiphene 25 mg1.93-0.35
Placebo1.94-0.70

[back to top]

Change From Baseline in Body Mass Index (BMI) at Week 48

BMI is calculated as weight (kg)/height(cm^2). A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionkg/cm^2 (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg35.45-1.43
Enclomiphene 25 mg37.38-2.29
Placebo38.05-4.38

[back to top]

Change From Baseline in Body Strength (Chest Press Weight) at Week 48

Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpounds (lbs) (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg169.0075.00
Enclomiphene 25 mg180.9376.90
Placebo151.5087.27

[back to top]

Change From Baseline in Body Strength (Leg Press Weight) at Week 48

Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpounds (lbs) (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg466.06406.92
Enclomiphene 25 mg464.20323.80
Placebo580.86351.50

[back to top]

Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter HbA1c. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpercentage of HbA1c (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg5.56-0.34
Enclomiphene 25 mg5.95-0.54
Placebo5.77-0.65

[back to top]

Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48

The HOMA-IR is the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) × fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg4.88-1.14
Enclomiphene 25 mg4.99-0.75
Placebo4.74-1.80

[back to top]

Change From Baseline in Lean Body Mass (LBM) at Week 48

LBM was assessed using dual-energy X-ray absorptiometry (DXA). A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionkg (Mean)
BaselineChange from Baseline to week 48
Enclomiphene 12.5 mg65.233.14
Enclomiphene 25 mg65.602.40
Placebo68.121.05

[back to top]

Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48

The DHT:T ratio was calculated as the value of DHT/value of T using the same units. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionratio (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg0.080.01
Enclomiphene 25 mg0.080.00
Placebo0.070.00

[back to top]

Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48

The T:E2 ratio was calculated as the value of T/value of E2 using the same units. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionratio (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg5.265.11
Enclomiphene 25 mg4.932.89
Placebo5.212.85

[back to top]

Change From Baseline in Waist Circumference at Week 48

A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventioncm (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg115.34-6.71
Enclomiphene 25 mg120.87-6.52
Placebo123.96-12.62

[back to top]

Change From Baseline in Weight at Week 48

A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionkg (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg114.13-4.36
Enclomiphene 25 mg121.75-6.15
Placebo124.58-14.51

[back to top]

Change From Baseline in Blood Leptin Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter leptin. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionng/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg9.881.14
Enclomiphene 25 mg16.552.63
Placebo15.16-2.27

[back to top]

Endometrial Thickness

Transvaginal sonographic measurement of maximal distance spanning endometrial- myometrial interphase on each endometrial stripe in a sagittal plane in the fundus of the uterus (NCT02710981)
Timeframe: Day of HCG administration

Interventionmillimeter (Mean)
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)6.6
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation)9.3

[back to top]

Uterine Blood Flow

Doppler ultrasound is used to measure the pulsatility index in both uterine arteries. Pulsatility index is a measure of the arterial resistance to blood flow. The higher the value of the pulsatility index, the more resistant the uterine arteries are, and hence the worst the outcome. (NCT02710981)
Timeframe: Day of HCG administration

Interventionindex (Mean)
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)2.4
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation)1.6

[back to top]

Clinical Pregnancy Rate

Identifying pregnancy through positive urinary HCG test plus sonographic detection of cardiac pulsations (NCT02710981)
Timeframe: At the end of a 28-day menstrual cycle.

InterventionParticipants (Count of Participants)
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)0
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation3

[back to top]

Clinical Pregnancy

Clinical Pregnancy: an intrauterine pregnancy with fetal heart motion determined by ultrasonography; No Clinical Pregnancy: no intrauterine pregnancy with fetal heart motion determined by ultrasonography (NCT02802865)
Timeframe: 6-7 weeks after treatment

InterventionParticipants (Count of Participants)
Letrozole1
Letrozole + Clomiphene3

[back to top]

Size of Largest Developing Follicle

Size of largest follicle on ultrasound (NCT02802865)
Timeframe: Cycle day 12-14

Interventionmm (Median)
Letrozole10
Letrozole + Clomiphene16

[back to top]

Pregnancy Loss

Pregnancy Loss: any pregnancy loss including biochemical pregnancy, ectopic pregnancy, and miscarriage; No Pregnancy Loss: no pregnancy loss including biochemical pregnancy, ectopic pregnancy, or miscarriage. (NCT02802865)
Timeframe: 9-10 months after treatment

InterventionParticipants (Count of Participants)
Letrozole2
Letrozole + Clomiphene1

[back to top]

Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level

Ovulation: mid-luteal progesterone > /=3 ng/mL. No ovulation: mid-luteal progesterone <3ng/mL. (NCT02802865)
Timeframe: 7 days following LH surge or at cycle day 21 if no LH surge was detected

InterventionParticipants (Count of Participants)
Letrozole15
Letrozole + Clomiphene27

[back to top]

Number of Developing Follicles

Number of follicles measuring > 10mm on ultrasound (NCT02802865)
Timeframe: Cycle day 12-14

Interventionfollicles (Median)
Letrozole0
Letrozole + Clomiphene1

[back to top]

Multiple Gestation

Multiple Gestation: an intrauterine pregnancy with multiple fetal heart rates determined by ultrasonography; No Multiple Gestation: either no intrauterine pregnancy, or an intrauterine pregnancy with a single fetal heart rate determined by ultrasonography (NCT02802865)
Timeframe: 9-10 months after treatment

InterventionParticipants (Count of Participants)
Letrozole0
Letrozole + Clomiphene0

[back to top]

Live Birth

Live Birth: delivery of a live infant; No Live Birth: no delivery of a live infant (NCT02802865)
Timeframe: 9-10 months after treatment

InterventionParticipants (Count of Participants)
Letrozole1
Letrozole + Clomiphene3

[back to top]

Endometrial Thickness

Thickness of endometrial lining assessed by ultrasound (NCT02802865)
Timeframe: Cycle day 12-14

Interventionmm (Mean)
Letrozole6.2
Letrozole + Clomiphene8.3

[back to top]

Conception

Conception: a positive serum or urinary test of hCG; No conception: Neither a positive serum or urinary test of hCG (NCT02802865)
Timeframe: 5 weeks after treatment

InterventionParticipants (Count of Participants)
Letrozole3
Letrozole + Clomiphene4

[back to top]

Normalized Testosterone - Week 24

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo214440274

[back to top]

Normalized Testosterone - Week 24

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 24

,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo268269446196
Anastrazole-placebo-clomiphene793519449630
Clomiphene-placebo-anastrazole537531447486

[back to top]

Normalized Testosterone - Week 8

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 8

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole133271270

[back to top]

Normalized Testosterone - Week 8

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 8

,,,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo484387607545
Anastrazole-placebo-clomiphene757296453676
Clomiphene-anastrazole-placebo566693216592
Clomiphene-placebo-anastrazole1316917527497
Placebo-anastrazole-clomiphene470298139296

[back to top]

SEP #1-3 Cumulative - Week 16

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 13-18
Placebo-clomiphene-anastrazole3

[back to top]

SEP #1-3 Cumulative - Week 16

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo33

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 16

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 16

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1111
Anastrazole-placebo-clomiphene1111
Clomiphene-anastrazole-placebo1111
Clomiphene-placebo-anastrazole1101
Placebo-anastrazole-clomiphene1111

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 13-18
Placebo-clomiphene-anastrazole30

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

,
Interventionscore on a scale (Number)
Patients 7-12Patients 19-24
Anastrazole-clomiphene-placebo33
Clomiphene-anastrazole-placebo33

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Clomiphene-placebo-anastrazole312

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene3333
Placebo-anastrazole-clomiphene2021

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

Interventionscore on a scale (Number)
Patients 1-6Patients 19-24
Placebo-clomiphene-anastrazole31

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Clomiphene-placebo-anastrazole121

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Anastrazole-clomiphene-placebo323
Clomiphene-anastrazole-placebo123

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene3323
Placebo-anastrazole-clomiphene4322

[back to top]

SHBG - Screen

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole26.220.916.9

[back to top]

SHBG - Screen

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

,,,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo13.930.723.528.6
Anastrazole-placebo-clomiphene35.212.617.522
Clomiphene-anastrazole-placebo2023.521.435.5
Clomiphene-placebo-anastrazole31.726.42011.6
Placebo-anastrazole-clomiphene24.126.814.830.6

[back to top]

SHBG - Week 16

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 16

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole33.316.717.2

[back to top]

SHBG - Week 16

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 16

,,,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo22.330.726.839.3
Anastrazole-placebo-clomiphene35.515.317.224.8
Clomiphene-anastrazole-placebo13.826.614.235
Clomiphene-placebo-anastrazole16.43122.813.9
Placebo-anastrazole-clomiphene17.72316.631

[back to top]

SHBG - Week 24

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 24

,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene23.634.117.5
Placebo-clomiphene-anastrazole29.713.817.3

[back to top]

SHBG - Week 24

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 24

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo15.124.433.8

[back to top]

SHBG - Week 24

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 24

,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Clomiphene-placebo-anastrazole25.225.320.113.7
Anastrazole-placebo-clomiphene41.81621.726
Anastrazole-clomiphene-placebo14.633.82923.2

[back to top]

SHBG - Week 8

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 8

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole23.924.114.3

[back to top]

SHBG - Week 8

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 8

,,,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1023.426.928.1
Anastrazole-placebo-clomiphene38.212.716.120.1
Clomiphene-anastrazole-placebo18.42621.642.7
Clomiphene-placebo-anastrazole29.827.230.920.9
Placebo-anastrazole-clomiphene21.625.717.630.7

[back to top]

SEP #1-3 Cumulative - Week 16

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 16

,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo2343
Clomiphene-placebo-anastrazole1333
Placebo-anastrazole-clomiphene2021
Anastrazole-placebo-clomiphene3333

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Screen

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Baseline

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1111
Anastrazole-placebo-clomiphene1111
Clomiphene-anastrazole-placebo1111
Clomiphene-placebo-anastrazole1111
Placebo-anastrazole-clomiphene1111
Placebo-clomiphene-anastrazole1111

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 16

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole010

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 24

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole011

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 24

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 24

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo011
Clomiphene-placebo-anastrazole110

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 24

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 24

,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene0101
Placebo-anastrazole-clomiphene1111
Anastrazole-clomiphene-placebo1101

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 8

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 8

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Anastrazole-clomiphene-placebo111

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 8

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 8

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene1101
Clomiphene-anastrazole-placebo1011
Clomiphene-placebo-anastrazole1101
Placebo-anastrazole-clomiphene1111
Placebo-clomiphene-anastrazole1001

[back to top]

EHS (Erectile Hardness Score) - Screen

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Baseline

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3333
Anastrazole-placebo-clomiphene3333
Clomiphene-anastrazole-placebo3333
Clomiphene-placebo-anastrazole2223
Placebo-anastrazole-clomiphene3333
Placebo-clomiphene-anastrazole3313

[back to top]

EHS (Erectile Hardness Score) - Week 16

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole421

[back to top]

EHS (Erectile Hardness Score) - Week 16

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 16

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3333
Anastrazole-placebo-clomiphene3341
Clomiphene-anastrazole-placebo2333
Clomiphene-placebo-anastrazole2343
Placebo-anastrazole-clomiphene3301

[back to top]

EHS (Erectile Hardness Score) - Week 24

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole321

[back to top]

EHS (Erectile Hardness Score) - Week 24

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo233

[back to top]

EHS (Erectile Hardness Score) - Week 24

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 24

,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3333
Anastrazole-placebo-clomiphene4341
Clomiphene-placebo-anastrazole2243
Placebo-anastrazole-clomiphene3311

[back to top]

EHS (Erectile Hardness Score) - Week 8

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 8

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1333
Anastrazole-placebo-clomiphene4333
Clomiphene-anastrazole-placebo1333
Clomiphene-placebo-anastrazole1232
Placebo-anastrazole-clomiphene1233
Placebo-clomiphene-anastrazole3411

[back to top]

Estradiol - Screen

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole15.918.615.9

[back to top]

Estradiol - Screen

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

,,,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo21.6913.39.5
Anastrazole-placebo-clomiphene8.119.320.115.5
Clomiphene-anastrazole-placebo9.621.316.226.6
Clomiphene-placebo-anastrazole13.511.414.111
Placebo-anastrazole-clomiphene18.410.913.126.8

[back to top]

Estradiol - Week 16

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 16

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole56.928.237

[back to top]

Estradiol - Week 16

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 16

Interventionpg/mL (Number)
Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene21.61528.3

[back to top]

Estradiol - Week 16

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 16

,,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo39.513.120.148.5
Clomiphene-anastrazole-placebo8.912.823.814.8
Clomiphene-placebo-anastrazole17.914.413.115.9
Placebo-anastrazole-clomiphene56.84.94.9

[back to top]

Estradiol - Week 24

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 24

,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene41.185.929.3
Placebo-clomiphene-anastrazole18.111.64.9

[back to top]

Estradiol - Week 24

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 24

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo16.26.619

[back to top]

Estradiol - Week 24

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 24

,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo22.512.525.522.2
Anastrazole-placebo-clomiphene43.949.136.439.4
Clomiphene-placebo-anastrazole9.559.24.9

[back to top]

Estradiol - Week 8

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 8

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole20.818.510

[back to top]

Estradiol - Week 8

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 8

Interventionpg/mL (Number)
Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene15.14.910.7

[back to top]

Estradiol - Week 8

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 8

,,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo11.279.77.4
Clomiphene-anastrazole-placebo49.870.125.151.7
Clomiphene-placebo-anastrazole94.54533.539.1
Placebo-anastrazole-clomiphene22.59.315.927.4

[back to top]

Free Testosterone - Screen

Measure of Free Testosterone (NCT03933618)
Timeframe: Baseline

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole6.275.829.49

[back to top]

Free Testosterone - Screen

Measure of Free Testosterone (NCT03933618)
Timeframe: Baseline

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo7.286.076.52
Placebo-anastrazole-clomiphene7.865.786.33

[back to top]

Free Testosterone - Screen

Measure of Free Testosterone (NCT03933618)
Timeframe: Baseline

,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo8.46.749.562.19
Anastrazole-placebo-clomiphene6.999.3112.277.27
Clomiphene-placebo-anastrazole8.829.94.867.71

[back to top]

Free Testosterone - Week 16

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 16

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Clomiphene-placebo-anastrazole12.679.636.63
Placebo-clomiphene-anastrazole19.2114.5716.38

[back to top]

Free Testosterone - Week 16

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 16

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo12.2714.711.22

[back to top]

Free Testosterone - Week 16

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 16

,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo14.168.8310.1714.98
Anastrazole-placebo-clomiphene16.375.75.989.46
Placebo-anastrazole-clomiphene17.4713.477.5811.62

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12
Placebo-anastrazole-clomiphene19.3125.27

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene19.3513.7413.54

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole8.6511.6315.49

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo6.2511.096.11

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo10.516.1111.825.82
Clomiphene-placebo-anastrazole11.2817.8918.1916.82

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

Interventionng/dl (Number)
Patients 1-6Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene21.815.1820.01

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole2.719.48.91

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo17.7219.3311.37
Placebo-anastrazole-clomiphene12.35.36.04

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo19.4615.6321.6117.44
Clomiphene-placebo-anastrazole35.2727.7921.7115.71

[back to top]

FSH - Screen

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Baseline

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.31.84.4

[back to top]

FSH - Screen

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Baseline

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo2.75.71.65.5
Anastrazole-placebo-clomiphene2.43.75.110
Clomiphene-anastrazole-placebo5.53.91.74.5
Clomiphene-placebo-anastrazole4.52.944.4
Placebo-anastrazole-clomiphene3.63.55.75.1

[back to top]

FSH - Week 16

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 16

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole10.72.68.3

[back to top]

FSH - Week 16

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 16

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene4.33.73.811.4
Clomiphene-anastrazole-placebo4.261.26.2
Clomiphene-placebo-anastrazole5.32.93.34.2
Placebo-anastrazole-clomiphene6.86.511.58.9
Anastrazole-clomiphene-placebo77.21.912.8

[back to top]

FSH - Week 24

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 24

,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene414.510.4
Placebo-clomiphene-anastrazole6.55.25.9

[back to top]

IIEF (International Index of Erectile Function) Score - Week 24

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole652745

[back to top]

FSH - Week 24

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 24

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo365

[back to top]

FSH - Week 24

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 24

,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo4.14.424.8
Anastrazole-placebo-clomiphene4.815.17.229.7
Clomiphene-placebo-anastrazole5.23.77.25.8

[back to top]

FSH - Week 8

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 8

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.42.24.7

[back to top]

FSH - Week 8

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 8

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo5.47.7311.3
Anastrazole-placebo-clomiphene4.36.28.320.3
Clomiphene-anastrazole-placebo8.27.81.86.1
Clomiphene-placebo-anastrazole16.23.036.38.1
Placebo-anastrazole-clomiphene4.14.264.4

[back to top]

IIEF (International Index of Erectile Function) Score - Screen

15 item self reported erectile function. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: At baseline

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo34575550
Anastrazole-placebo-clomiphene43574652
Clomiphene-anastrazole-placebo57454155
Clomiphene-placebo-anastrazole41324547
Placebo-anastrazole-clomiphene24553262
Placebo-clomiphene-anastrazole57365818

[back to top]

IIEF (International Index of Erectile Function) Score - Week 16

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole663359

[back to top]

IIEF (International Index of Erectile Function) Score - Week 16

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 16

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo45435362
Anastrazole-placebo-clomiphene53566238
Clomiphene-anastrazole-placebo35503751
Clomiphene-placebo-anastrazole45555847
Placebo-anastrazole-clomiphene37381518

[back to top]

IIEF (International Index of Erectile Function) Score - Week 24

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo424360

[back to top]

IIEF (International Index of Erectile Function) Score - Week 24

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 24

,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo12546052
Clomiphene-placebo-anastrazole52357247
Placebo-anastrazole-clomiphene41451714
Anastrazole-placebo-clomiphene70606559

[back to top]

IIEF (International Index of Erectile Function) Score - Week 8

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 8

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo25455563
Anastrazole-placebo-clomiphene55515965
Clomiphene-anastrazole-placebo32633270
Clomiphene-placebo-anastrazole20456545
Placebo-anastrazole-clomiphene35372853
Placebo-clomiphene-anastrazole66724325

[back to top]

LH - Screen

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Baseline

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.52.46

[back to top]

LH - Screen

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Baseline

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3.53.41.16.3
Anastrazole-placebo-clomiphene3.63.83.54.1
Clomiphene-anastrazole-placebo3.82.44.14.7
Clomiphene-placebo-anastrazole6.84.13.35.9
Placebo-anastrazole-clomiphene3.41.73.16.8

[back to top]

LH - Week 16

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 16

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole13.95.213

[back to top]

LH - Week 16

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 16

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo6.86.91.97.8
Anastrazole-placebo-clomiphene4.64.82.14.3
Clomiphene-anastrazole-placebo4.26.32.26.6
Clomiphene-placebo-anastrazole5.44.91.94.9
Placebo-anastrazole-clomiphene8.93.86.47.4

[back to top]

LH - Week 24

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 24

,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene7.710.58.1
Placebo-clomiphene-anastrazole52.97.1

[back to top]

LH - Week 24

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 24

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo3.45.94.7

[back to top]

LH - Week 24

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 24

,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo36.12.22.7
Anastrazole-placebo-clomiphene4.112.65.415.1
Clomiphene-placebo-anastrazole6.46.47.65.4

[back to top]

LH - Week 8

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 8

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.63.36.7

[back to top]

LH - Week 8

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 8

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene5.146.911.5
Clomiphene-anastrazole-placebo9.910.76.17.5
Clomiphene-placebo-anastrazole17.312.64.76.9
Placebo-anastrazole-clomiphene6.31.937.3
Anastrazole-clomiphene-placebo9.15.22.94.2

[back to top]

Normalized Testosterone - Screen

Normalized at >350ng/dl (NCT03933618)
Timeframe: Baseline

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole315214321

[back to top]

Normalized Testosterone - Screen

Normalized at >350ng/dl (NCT03933618)
Timeframe: Baseline

,,,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo20529334795
Anastrazole-placebo-clomiphene330237328291
Clomiphene-anastrazole-placebo226194268306
Clomiphene-placebo-anastrazole367300206244
Placebo-anastrazole-clomiphene321243148289

[back to top]

Normalized Testosterone - Week 16

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 16

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole696396585

[back to top]

Normalized Testosterone - Week 16

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 16

,,,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo437337329609
Anastrazole-placebo-clomiphene591200191323
Clomiphene-anastrazole-placebo338451124456
Clomiphene-placebo-anastrazole391403206288
Placebo-anastrazole-clomiphene502520283484

[back to top]

Normalized Testosterone - Week 24

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 24

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene596972195
Placebo-clomiphene-anastrazole412375487

[back to top]

Changes in Endometrial Thickness

Changes in endometrial thickness between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionmm (Mean)
EGCG Daily Alone.-1.9
EGCG With Clomiphene Citrate1.4
EGCG With Letrozole0.6

[back to top]

Changes in Total Bilirubin

Changes in total bilirubin between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionmg/dL (Mean)
EGCG Daily Alone.0.1
EGCG With Clomiphene Citrate0
EGCG With Letrozole0

[back to top]

Changes in ALT/SGPT

Changes in alanine aminotransferase /SGPT between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionU/L (Mean)
EGCG Daily Alone.1.1
EGCG With Clomiphene Citrate4.4
EGCG With Letrozole-1.0

[back to top]

Changes in Alkaline Phosphatase

Changes in Alkaline Phosphatase between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionU/L (Mean)
EGCG Daily Alone.-1.5
EGCG With Clomiphene Citrate-5.6
EGCG With Letrozole-6.0

[back to top]

Change in Serum Folate Level Between MTHFR677-Wild Type (WT) Group and MTHFR677-Hetero Group

Change in serum folate levels between MTHFR677-Wild Type (WT) group and MTHFR677-Hetero group (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionng/mL (Mean)
MTHFR677-Wild Type (WT) Group-3.2
MTHFR677-Hetero Group-2.0

[back to top]

Change in Serum Folate Level Between MTHFR1298-Wild Type (WT) Group and MTHFR1298-Hetero Group

Change in serum folate levels between MTHFR1298-Wild Type (WT) group and MTHFR1298-Hetero group (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionng/mL (Mean)
MTHFR1298-Wild Type (WT) Group-1.5
MTHFR1298-Hetero Group-3.8

[back to top]

Change in Serum Folate Level Between DHFR-Wild Type (WT) Group and DHFR-Hetero or Homo Group.

Change in serum folate levels between DHFR-Wild Type (WT) group and DHFR-Hetero or homo group. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionng/mL (Mean)
DHFR-Wild Type (WT) Group-3.9
DHFR-Hetero or Homo Group.-2.1

[back to top]

Changes in Estrogen (E2)

Changes in Estrogen (E2) between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionpg/mL (Mean)
EGCG Daily Alone.-50.9
EGCG With Clomiphene Citrate-49.4
EGCG With Letrozole-50.2

[back to top]

Changes in Epigallocatechin Gallate (EGCG)

Changes in epigallocatechin gallate (EGCG) from Visit 1 to Visit 4 (end of study). EGCG levels measured at 1 hour after taking study medication were used for both visits. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionnM (Median)
EGCG Daily Alone.5.8
EGCG With Clomiphene Citrate256.3
EGCG With Letrozole86.4

[back to top]

Changes in Epigallocatechin (EGC)

Changes in epigallocatechin (EGC) from Visit 1 to Visit 4 (end of study). EGC levels measured at 1 hour after taking study medication were used for both visits. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionnM (Median)
EGCG Daily Alone.-58.9
EGCG With Clomiphene Citrate8.9
EGCG With Letrozole35.4

[back to top]

Changes in Epicatechin Gallate(ECG)

Changes in epicatechin gallate(ECG) from Visit 1 to Visit 4 (end of study). ECG levels measured at 1 hour after taking study medication were used for both visits. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionnM (Median)
EGCG Daily Alone.7.6
EGCG With Clomiphene Citrate64.1
EGCG With Letrozole60.3

[back to top]